



(11) **EP 1 776 041 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
26.06.2019 Bulletin 2019/26

(51) Int Cl.:
A61B 5/0444 (2006.01) **A61B 5/024** (2006.01)
A61B 5/0488 (2006.01) **A61B 5/03** (2006.01)
A61B 5/00 (2006.01) **A61B 5/0452** (2006.01)

(21) Application number: **05767705.6**

(86) International application number:
PCT/US2005/018753

(22) Date of filing: **27.05.2005**

(87) International publication number:
WO 2005/117692 (15.12.2005 Gazette 2005/50)

(54) **MATERNAL-FETAL MONITORING SYSTEM**
MUTTER-FÖTUS-ÜBERWACHUNGSSYSTEM
SYSTEME DE SURVEILLANCE MATERNELLE/FOETALE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(56) References cited:
WO-A-00/54650 WO-A-03/003905
WO-A-03/028550 WO-A-2005/044101
US-A- 4 781 200

(30) Priority: **28.05.2004 US 857107**

(43) Date of publication of application:
25.04.2007 Bulletin 2007/17

(73) Proprietors:
• **University of Florida Research Foundation, Inc.**
Gainesville, FL 32611 (US)
• **Convergent Engineering, Inc.**
Gainesville FL 32608 (US)

- **MAROSSERO D E ET AL: "Independent components analysis for fetal electrocardiogram extraction: a case for the data efficient mermaid algorithm" NEURAL NETWORKS FOR SIGNAL PROCESSING, 2003. NNSP'03. 2003 IEEE 13TH WORKSHOP ON TOULOUSE, FRANCE SEPT. 17-19, 2003, PISCATAWAY, NJ, USA,IEEE, 17 September 2003 (2003-09-17), pages 399-408, XP010712475 ISBN: 0-7803-8177-7**
- **POTTER M ET AL: "Competing ICA techniques in biomedical signal analysis" ELECTRICAL AND COMPUTER ENGINEERING, 2001. CANADIAN CONFERENCE ON MAY 13-16, 2001, PISCATAWAY, NJ, USA,IEEE, vol. 2, 13 May 2001 (2001-05-13), pages 987-992, XP010550969 ISBN: 0-7803-6715-4**
- **VIGNERON V ET AL: "Fetal electrocardiogram extraction based on non-stationary ICA and wavelet denoising", SIGNAL PROCESSING AND ITS APPLICATIONS, 2003. PROCEEDINGS. SEVENTH INTERNATIONAL SYMPOSIUM ON JULY 1-4, 2003, PISCATAWAY, NJ, USA,IEEE, vol. 2, 1 July 2003 (2003-07-01), pages 69-72, XP010653305, ISBN: 978-0-7803-7946-6**

(72) Inventors:
• **MAROSSERO, Dorothee**
Gainesville, FL 32610 (US)
• **EULIANO, Tammy, Y.**
Gainesville, FL 32608 (US)
• **EULIANO, Neil, Russell, II**
Gainesville, FL 32608 (US)
• **PRINCIPE, Jose, C.**
Gainesville, FL 32653-3900 (US)

(74) Representative: **de Haan, Poul Erik**
Philips International B.V.
Philips Intellectual Property & Standards
High Tech Campus 5
5656 AE Eindhoven (NL)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 776 041 B1

DescriptionBackground of Invention

[0001] Assessment of the fetus during pregnancy, and particularly during labor and delivery, is an essential but yet elusive goal. While most patients will deliver a healthy child with or without monitoring, more than 5 out of every 1,000 deliveries of a viable fetus near term is stillborn, with half having an undetermined cause of death. (National Vital Statistics System (NVSS), CDC, NCHS as published in "Healthy People 2010, Understanding and Improving Health: Chapter 16," co-authored by the Centers for Disease Control and Prevention and Health Resources and Services Administration, 2nd Edition, U.S. Government Printing Office, November 2000). The risk of this unfortunate consequence is increased in a subgroup of "high risk" patients (e.g. diabetics). In addition to regular obstetric observation, after 23 weeks gestation antepartum ("in utero") fetal monitoring consists of the following (in order of complexity):

1. maternal report of fetal movement;
2. non-stress test (NST) - monitor fetal heart rate (FHR) by ultrasound, looking for baseline rate, variability and presence of accelerations above the baseline;
3. contraction stress test (CST) - response of the FHR to uterine contractions, either natural or induced; and
4. biophysical profile (BPP) - NST plus ultrasonographic evaluation of fetal movements and amniotic fluid volume.

Despite their wide acceptance, these tests offer limited predictive value, and give only a glimpse of the fetus at the time of testing. For high risk patients, once or twice weekly surveillance is often indicated, entailing both expense and inconvenience for the patient.

[0002] Intrapartum fetal surveillance is accomplished routinely with intermittent auscultation or continuous Doppler monitoring of the FHR, together with palpation or tocodynamometry (strain gauge) monitoring of contractions. When indicated, more invasive monitors are available, but require ruptured membranes/adequate cervical dilation, and entail some risk, primarily infectious. These monitors include, without limitation:

1. fetal scalp electrode - a wire electrode inserted into the fetal scalp;
2. intra-uterine pressure catheter (IUPC) - enables quantitative measurement of contractions; and
3. fetal scalp sampling - a blood sample drawn for pH analysis.

[0003] Contraction detection allows monitoring of the progress of labor. The tocodynamometer detects only the presence or absence of tension on the abdomen (whether from uterine contraction or maternal movement), and often fails in the presence of obesity. When cervical dilation lags behind the anticipated labor curve, oxytocin is often indicated to induce a more effective contraction pattern. Safe titration of the oxytocin may require accurate determination of "montevideo units" which measure the strength of uterine contractions over 10 minutes. This requires the more invasive IUPC, a catheter placed into the uterus, alongside the fetus, to measure the pressure generated by uterine contractions.

[0004] The rationale for use of intrapartum electronic fetal monitoring (EFM) assumes that FHR abnormalities accurately reflect hypoxia (inadequate oxygen to the fetus), and that early recognition of this could induce intervention to improve outcome for both mother and fetus. Unfortunately, numerous studies have failed to identify this improved outcome with the use of EFM in low-risk deliveries. In fact some studies have actually shown an increase in morbidity from a higher operative delivery rate. Perhaps this should not be surprising in light of the variability in interpretation of FHR tracings and their lack of specificity for hypoxia. Yet, continuous EFM remains the standard of care in US hospitals, in large part due to medicolegal concerns. Meanwhile researchers seek an alternative monitor, specific for fetal well being, preferably one that is non-invasive and comfortable for the mother, with reliable, reproducible interpretation. Recently, analysis of the fetal ECG (electrocardiogram) has held promise, with some features of the waveform more specifically indicating fetal hypoxia. Use of the waveform analysis reduced the incidence of severe metabolic acidosis at birth, while necessitating fewer scalp samples and operative deliveries. Unfortunately, acquisition of the FECG was through the fetal scalp electrode described above which is both invasive and limited in its application. The necessity for access to the fetal scalp requires both adequate cervical dilation and ruptured membranes, eliminating this procedure for antepartum fetal surveillance, as well as early labor.

[0005] Non-invasive acquisition of the FECG is a recognized issue of mixed signals. Electrodes placed on the skin surface will record all transmitted electrical activity including maternal ECG, maternal skeletal muscle, uterine muscle, fetal skeletal muscle, and fetal ECG.

[0006] Uterine contractions are the result of the coordinated actions of individual myometrial cells. At the cellular level, the contractions are triggered by a voltage signal called an action potential. During pregnancy, cellular electrical connectivity increases such that the action potential propagates to produce a coordinated contraction involving the entire uterus. The action potential during a uterine contraction can be measured with electrodes placed on the maternal

abdomen resulting in a uterine EMG signal (hereinafter referred to as "EHG": electrohysterogram). Specifically, the EHG signal can be processed to produce a signal that is similar to the standard uterine activity signal from the tocodynamometer or IUPC. The EHG provides contraction frequency and duration information. To date, EHG signals have not been used in assessing the intra-uterine pressure or predicting montevideo units.

[0007] Postpartum, continuous uterine contraction is required to minimize uterine bleeding from the placental detachment site. Hemorrhage is the leading cause of peripartum maternal death, and most of these are postpartum hemorrhage due to this "uterine atony." Current monitoring consists of serial uterine palpation at intervals of several hours. Diagnosis is usually made by patient complaint of severe bleeding, or hypovolemic shock (from hemorrhage). Neither IUPC nor tocodynamometer monitoring is available at this time. The EHG would provide a unique means for monitoring the uterine tone, providing an early warning of atony and potential hemorrhage.

[0008] Devices that utilize invasive techniques for monitoring fetal health include those disclosed in U.S. Patent Nos. 6,594,515; 6,115,624; 6,058,321; 5,746,212; 5,184,619; 4,951,680; and 4,437,467.

[0009] To address the inadequacies noted above, various methods have been proposed for use in processing maternal abdominal signals to provide more accurate FECG extraction. These methods include subtractive filtering (see, for example, U.S. Patent No. 4,945,917), adaptive filtering (see, for example, Widrow, B. et al., "Adaptive Noise Canceling: Principals and Applications," Proc. IEEE, 63(12):1692-1716 (Dec. 1975); Adam, D. and D. Shavit, "Complete Fetal ECG Morphology Recording by Synchronized Adaptive Filtration," Med. & Biol. Eng. & Comput., 28:287-292 (July 1990); Ferrara, E. and B. Widrow, "Fetal Electrocardiogram Enhancement by Time Sequenced Adaptive Filtering," IEEE Trans. Biomed. Eng., BME-29(6):458-460 (June 1982); U.S. Patent Nos. 4,781,200 and 5,042,499), orthogonal basis (Longini, R. et al., "Near Orthogonal Basis Function: A Real Time Fetal ECG Technique," IEEE Trans. On Biomedical Eng., BME-24(1):39-43 (Jan. 1977); U.S. Patent No. 5,042,499), linear combination (Bergveld, P. et al., "Real Time Fetal ECG Recording," IEEE Trans. On Biomedical Eng., BME-33(5):505-509 (May 1986)), single value decomposition (Callaerts, D. et al., "Comparison of SVD Methods to Extract the Fetal Electrocardiogram from Cutaneous Electrodes Signals," Med. & Biol. Eng. & Comput., 28:217-224 (May 1990); U.S. Patent No. 5,209,237), and MECG averaging and correlation (Abboud, S. et al., "Quantification of the Fetal Electrocardiogram Using Averaging Technique," Comput. Biol. Med., 20:147-155 (Feb. 1990); Cerutti, S. et al., "Variability Analysis of Fetal Heart Rate Signals as Obtained from Abdominal Electrocardiographic Recordings," J. Perinat. Med., 14:445-452 (1986); J. Nagel, "Progresses in Fetal Monitoring by Improved Data Acquisition," IEEE Eng. Med. & Biol. Mag., 9-13 (Sept. 1984); Oostendorp, T. et al., "The Potential Distribution Generated by Fetal Heart at the Maternal Abdomen," J. Perinat. Med., 14:435-444 (1986); U.S. Patent No. 5,490,515). These methods, unfortunately, do not reliably enable continuous extraction of maternal-fetal data or cannot capture a comprehensive account of maternal-fetal health based on a combination of test results (*i.e.*, fetal heart rate, fetal ECG, maternal ECG, and maternal uterine activity (EHG)).

[0010] Marossero et al. ("Independent components analysis for fetal electrocardiogram extraction: a case for the data efficient mermaid algorithm", NEURAL NETWORKS FOR SIGNAL PROCESSING, NNSP103, IEEE 13TH WORKSHOP ON TOULOUSE, FRANCE, 17 September 2003, pages 399-408, XP010712475, ISBN: 0-7803-81 77-7) discloses a method to collect signals, which are mixtures of the maternal electrocardiogram (MECG), the fetal electrocardiogram (FECG), and interfering noise. Marossero *et al.* further discloses a way to separate fetal signals from noisy elements.

[0011] Recently, magnetocardiography has been utilized in extracting fetal ECG (see, for example, Sturm, R. et al., "Multi-channel magnetocardiography for detecting beat morphology variations in fetal arrhythmias," Prenat Diagn, 24(1):1-9 (Jan. 2004); and Stinstra, J. et al, "Multicentre study of fetal cardiac time intervals using magnetocardiography," BJOG, 109(11):1235-43 (Nov. 2002)). Unfortunately, magnetocardiography is limited in application, technologically complex, and difficult to administer to assess accurate fetal ECG readings.

[0012] Accordingly, a cost-effective, portable monitoring system for both the mother and fetus is needed that can continuously monitor, in real-time, and accurately extract and evaluate maternal/fetal heart rates and ECGs, maternal EHG, as well as fetal position.

Brief Summary of the Invention

[0013] The present invention provides an effective, all-inclusive system for maternal-fetal monitoring during both antepartum and intrapartum stages of pregnancy. In one embodiment, the system uses a set of electrodes on the maternal abdomen to extract clinical data. Clinically relevant data that can be extracted from these electrodes include, without limitation, maternal electrocardiogram (ECG), maternal uterine EMG (EHG), fetal heart rate (FHR), fetal ECG, and determination of fetal position. The maternal-fetal monitoring system of the present invention can be used for antepartum and/or intrapartum monitoring.

[0014] In one aspect of the invention, the system comprises (1) at least two surface sensors to receive a mixture of maternal and fetal vital signals; and (2) a computing means configured to analyze the mixture of maternal and fetal vital signals from the sensors, said computing means comprising hardware and Software, wherein said Software comprises an independent component analysis function configured to separate maternal from fetal vital signals in real-time, and

said Software configured to enable automatic selection of maternal and fetal vital signals separated by the independent component analysis function, wherein said Software further comprises a quality assessing function configured to establish the quality of the maternal and fetal vital signals separated by the independent component analysis function, wherein the quality assessment function configured to utilize trust factor operations at the output of the independent component analysis function and wherein, at the output of the independent component analysis operations, heart beat detection algorithm operations are performed, wherein the trust factor operations are performed on estimated signal results and wherein the trust factor operations include computing a first continuous probability function (Pf) that the output signal is a fetal signal and a second continuous probability function (Pm) that the output signal is a maternal signal.

[0015] Other aspects of the present invention are provided in accordance with the accompanying claims.

[0016] Aspects, embodiments, examples or methods of the present disclosure which do not fall within the scope of the appended claims do not form part of the present invention.

[0017] The system also incorporates an intelligence means, such as a neural network system, that utilizes the clinical data to analyze and interpret fetal well-being (both antepartum and intrapartum). The intelligence means can also offer clinical advice including, but not limited to, fetal distress, maternal distress, labor progress, contraction effectiveness, uterine rupture, likelihood of delivery within a defined period (*i.e.*, preterm evaluation), and likelihood of successful vaginal delivery. Furthermore, immediate postpartum monitoring of the EHG can provide the user with information regarding uterine tone (*i.e.*, pre-delivery and/or post-delivery). For example, the subject monitoring system can signal uterine atony and prompt early intervention.

[0018] The present disclosure provides comprehensive monitoring/classification of maternal-fetal health through the use of novel methods for accurately extracting maternal ECG, heart rate and uterine activity (EHG), as well as fetal ECG, heart rate, and positioning, including (1) using an independent component analysis algorithm (ICA) to separate maternal and fetal signals; (2) using signal processing means for automatically determining the fetal and maternal channels, (3) using signal processing means for providing contraction information (4) using signal processing means for providing undistorted ECG waveforms (P and T waves and QRS complex) post-ICA source separation; (5) using a surface electrode mesh to provide accurate positioning and repeatability in extracting fetal ECG signals, higher signal quality and higher separation performance, and enhance patient comfort; and (6) using a neural network to present clinical observations regarding maternal and fetal health (*i.e.*, fetal distress, maternal distress, labor progress, contraction effectiveness, likelihood of delivery within a defined period) in view of clinical services to be provided.

[0019] The algorithms utilized in the present invention are particularly advantageous in that they enable the maternal-fetal monitoring system to provide real-time results as well as automatic and real-time classification of maternal and fetal channels of output using portable, low power digital signal processor implementations.

[0020] The present disclosure also provides an EHG monitor. In one embodiment, the monitoring system includes at least one sensor to acquire a uterine EMG signal and a signal processor for generating a signal representative of uterine activity (EHG). The EHG indicates uterine contraction frequency and contraction duration information. Additionally, the EHG approximates a signal that would be acquired using either a toco or, after processing, approximates a signal that would be acquired using an intra-uterine pressure catheter (IUPC) sensor. In a preferred embodiment, the electrodes of the system would simultaneously collect both ECG and EHG information.

[0021] The maternal-fetal monitoring system of the present invention is particularly advantageous as either an add-on or stand-alone monitor for use in a variety of settings. As an all-inclusive monitoring system, the maternal-fetal monitoring system of the present invention can be effectively used in place of non-stress tests, contraction stress tests, biophysical profiles, preterm labor evaluations, and existing fetal monitoring systems. Moreover, by providing an all-inclusive monitoring system, which includes an intelligence means for offering clinical advice, the present invention can provide improved prediction of maternal/fetal well-being as well as prediction of labor progress as compared to existing fetal monitoring systems. The system also provides the ability to monitor maternal and/or fetal well-being during surgery (both cesarean section and non-obstetric surgery in the pregnant patient) without interfering with the sterile field. In addition, the system provides the only means to continuously monitor postpartum uterine tone.

[0022] Certain embodiments can be portable for use in a clinical office/hospital setting as well as at home. Because the maternal-fetal monitoring system of the present invention can be used in a home setting, trips to the hospital or clinical office can be limited. For example, the monitoring system of the invention can limit trips to the hospital to investigate contractions (*i.e.*, Braxton Hicks contractions) versus labor for both pre-term and at term mothers that must travel a fair distance to the hospital.

[0023] The maternal-fetal monitoring system of the present invention enables non-invasive capture of fetal ECG results with much less risk to the fetus' health and no limitation on cervical dilation or ruptured membranes, as is generally presented with use of current systems and methods for monitoring fetal ECG. The system eliminates uncomfortable equipment, and can be used intraoperatively during Cesarean delivery as well as during non-obstetric surgery in the pregnant patient (*i.e.*, appendectomy or cholecystectomy where ultrasound would be in the sterile field).

Brief Description of Drawings**[0024]**

Figure 1 illustrates a set of electrodes positioned on a maternal abdomen.

Figure 2 illustrates one embodiment of the maternal-fetal monitoring system, wherein the monitoring system is ambulatory.

Figure 3 illustrates a computing means used in the subject invention.

Figures 4A-F are examples of computer user-interface pages presented to a user.

Figure 5 illustrates a flow diagram illustrating steps for operating a maternal-fetal monitoring system.

Figure 6 is a graphical illustration of the probability of a vital signal being from the mother and the fetus, as extracted by the monitoring system of the invention.

Figure 7 is a flow diagram illustrating steps for determining the fetal heart electrical influence on different sensors.

Figure 8 illustrates models for fetal heart vectors and maternal heart vectors.

Figures 9A-B illustrate an example of a vertex presentation when using sensors positioned on a mesh as provided in Figure 2.

Figure 10 is an illustration comparing simulated ECG waveform versus collected ECG waveform for each electrode (V_{1-6} , RA, and LA).

Figure 11 illustrates a simulated fetal ECG waveform for a specific fetal position as compared to collected ECG waveform for each electrode (V_{1-6} , RA, and LA).

Figures 12A-C illustrate various templates corresponding to different fetal presentations in the maternal abdomen

Figure 13 illustrates the steps of training and testing processes for an intra-uterine pressure sensor.

Figure 14 is a flow diagram illustrating a maternal-fetal monitoring system.

Figures 15A-C graphically illustrate intra-uterine pressure signals from collected versus training sensor signals for signals collected by abdominal sensors of the subject invention as compared to signals provided by a commercially available intra-uterine pressure catheter.

Figure 16 are graphical illustrations of contraction curves of sensors channels 1_{V1-V2} and 1_{V3-V4} of the subject invention in comparison to contraction curves provided by a commercially available Corometrics monitoring system.

Figure 17 are graphical illustrations of contractions detected using the monitoring system of the subject invention as compared to a commercially available Corometrix monitoring system.

Figure 18 are graphical illustrations comparing observed time intervals between successive contractions as time progresses using a monitoring system of the present disclosure (EHG2) versus a commercially available Corometrix monitoring system.

Figures 19A-D are graphical illustrations of contraction consistency between a monitoring system of the present disclosure and a commercially available Corometrics monitoring system.

Detailed Disclosure

[0025] The subject invention provides a system for non-invasive, comprehensive monitoring of maternal-fetal vital signs for use in interpreting maternal-fetal health as well as in offering support/advice in making clinical decisions. The system comprises (1) at least two surface sensors to receive a mixture of maternal and fetal vital signals; and (2) a computing means configured to analyze the mixture of maternal and fetal vital signals from the sensors, said computing means comprising hardware and Software, wherein said Software comprises an independent component analysis function configured to separate maternal from fetal vital signals in real-time, and said Software configured to enable automatic selection of maternal and fetal vital signals separated by the independent component analysis function, wherein said Software further comprises a quality assessing function configured to establish the quality of the maternal and fetal vital signals separated by the independent component analysis function, wherein the quality assessment function configured to utilize trust factor operations at the output of the independent component analysis function and wherein, at the output of the independent component analysis operations, heart beat detection algorithm operations are performed, wherein the trust factor operations are performed on estimated signal results and wherein the trust factor operations include computing a first continuous probability function (Pf) that the output signal is a fetal signal and a second continuous probability function (Pm) that the output signal is a maternal signal.

[0026] The computing means for receiving and analyzing sensor input (vital signs) as disclosed can be used to accurately determine clinical data, including without limitation, maternal and fetal vital signs, fetal presentation, contraction efficiency, and pharmaceutical efficacy (*i.e.*, titration of oxytocin). A graphical user interface can be included with the systems of the invention to display clinical data as well as enable user-interaction.

[0027] In one embodiment, the system of the present disclosure further includes an intelligence system that can use the clinical data generated by the processor in offering support/advice for making clinical decisions (*i.e.*, to interpret fetal

well-being, labor progress, likelihood of delivery within a period of time; and likelihood of successful vaginal delivery). An intelligence system of the subject invention can include, but is not limited to, artificial neural networks, fuzzy logic, evolutionary computation, knowledge-based systems, optimal linear or nonlinear filtering, and artificial intelligence.

[0028] In one embodiment, a neural network system is provided in the monitoring system of the invention to enable real-time assistance in providing additional clinical data (*i.e.*, classification of fetal health and detection of abnormalities, for example arrhythmias, bradycardia, tachycardia, or problems with umbilical cord or with fetal presentation).

[0029] The computing means is preferably a digital signal processor, which can (1) automatically, accurately, and in real-time, extract maternal and fetal vital signals, including ECG signals, and EHG signals from sensor input; (2) assess the quality of clinical data (*i.e.*, maternal and fetal vital signals) provided by the processor in view of environmental noise; (3) determine fetal presentation; (4) determine contraction efficiency; (5) determine probability of vaginal delivery; (6) determine time to delivery; (7) determine arrested descent; (8) determine uterine rupture, and (9) determine labor progress.

[0030] In one embodiment as disclosed, the system of the subject invention is stationary. For example, the system of the invention can be used within a healthcare setting (*i.e.*, hospital, physician's office).

[0031] In another embodiment, the system of the subject invention is portable for use outside of a healthcare setting (*i.e.*, home use). In a related embodiment, a portable system enables continuous monitoring of the mother and fetus for beneficial assessment of maternal-fetal wellbeing (*i.e.*, in general, specific activities/environments - exercising and/or presence of effective contraction to determine labor). Such monitoring can provide information not only to the user (*i.e.*, mother) but also provide off-site information to the healthcare provider. For example, continuous monitoring can be accomplished remotely from the location of mother/fetus by the healthcare provider.

Definitions

[0032] As used herein, the term "vital signs" or "vital signals" includes maternal and fetal heart rate, respiratory rate, ECG results, and EHG.

[0033] As used herein, the term "clinical data" refers to information obtained from the analysis and/or interpretation of maternal-fetal vital signs. Clinical data can include, but is not limited to, classification of maternal and fetal health (*i.e.*, normal fetal heart rate or normal maternal heart rate during labor), fetal presentation, labor progress, contraction efficiency, pharmaceutical efficacy/toxicity, arrhythmias, bradycardia, tachycardia, problems with umbilical cord or with fetal presentation, and postpartum uterine atony.

[0034] The term "patient," as used herein refers to a mother and/or fetus. The term patient includes mammals to which monitoring systems according to the present invention are provided. Mammalian species that benefit from the disclosed monitoring systems include, but are not limited to, humans, domesticated animals (*i.e.*, dogs, cats, horses), as well as rare animals that require observation (*i.e.*, endangered mammals).

Sensors

[0035] In accordance with the subject invention, vital signs (and corresponding clinical data) are extracted in real time using sensors that do not endanger fetal health. In a preferred embodiment, a set of electrodes is used to sense maternal-fetal vital signs.

[0036] One embodiment of the invention utilizes a set of electrodes (at least 4 electrodes but preferably 10 up to 20 electrodes) provided on a mesh (or vest), wherein the mesh can function as an electrode-stabilization component. Such a mesh can be prepared using any suitable material that permits the mesh to be both lightweight and comfortable. The benefits of a system of this type are the ease of use and reduction of preparation time required to appropriately place the electrodes on a patient. For example, preparation time can be reduced from 15-30 minutes for adhesive-based disposable electrodes to about 5 minutes using a mesh of the invention. In addition, a mesh of electrodes according to the subject invention would permit consistent (and repeatable) extraction of maternal-fetal vital signs.

[0037] As illustrated in Figure 1, a set of eight electrodes are positioned such that four electrodes, **1a-d**, are placed on the vertical mid-line of the abdomen, above and below the maternal navel. The remaining four electrodes are positioned so that two electrodes are to the left, **2a-b**, and to electrodes are to the right, **3a-b**, of the mid-line vertically aligned four electrodes. In a preferred embodiment, the left leg and driven right leg reference electrodes would be placed in the center of the abdomen between electrodes 2a and 2b.

Amplifier

[0038] An amplifier is provided to amplify maternal-fetal vital signals collected by the set of sensors of the invention. Amplifiers for use in the collection of vital signals are known in the art. For example, traditional ECG amplifiers amplify an input signal from an electrode sensor in the range of 1mV to 5mV in amplitude. Unfortunately, such amplifiers are

not always suitable for fetal ECG because the fetal ECG signal is typically in the range of about 10 μ V to 50 μ V in amplitude. Thus, the fetal ECG is often hidden below the noise floor. To address this, the amplifier of the subject invention is calibrated such that the fetal vital signals are sufficiently amplified for detection while preserving the dynamic range of the maternal vital signals.

[0039] In one embodiment, the amplifier of the invention is a high-resolution, low-noise, unipolar amplifier (*i.e.*, all channels of signals are referenced from a single electrode). In a preferred embodiment, a driven right leg (DRL) circuit is utilized to actively suppress noise and improve the common mode rejection ratio (CMRR) of the amplifier so that the fetal ECG is above the noise floor. More preferably, the amplifier amplifies input signals by 1,500 times, has eight channels, can be adjusted between 4,000 V/V and 10,000 V/V, and has a CMRR of at least 80 dB.

[0040] In another embodiment, as illustrated in Figure 2, the amplifier **5** has a 15-pin D-sub connector that interfaces with an electrode cable **4** connected to a set of electrodes **1a-d, 3a-b**. Preferably, the electrode cable is a 10-lead shielded ECG cable. A shielded cable is essential to reduce any noise interference due to frequencies from various power sources. But other means of providing shielding such as fiber optical cables are preferred. In one embodiment, amplifier output can interface to an analog-to-digital converter (A/D) converter. A power supply is provided to operate the amplifier. Preferably, the power supply includes an adapter that is a 12V AC-DC medical grade power supply adapter and a power converter, which is provided to protect the patient from leakage currents.

[0041] The A/D converter can be situated in the amplifier or in a computing means **6** of the invention. An A/D converter can be selected from a variety of suitable types known in the art that have the desired dynamic input range. A/D converters encode sensor signals for respective sensor channels into a digital format, such as a 16 bit format, at a desired sampling rate, such as 200Hz.

Filters

[0042] At least one filter can be included in the maternal-fetal monitoring system. Filters of the invention can be applied to sensor signals prior to processing, during processing, or post processing as performed in the computing means; or some combination thereof. In certain embodiments, the filter(s) are applied at the amplifier to signals communicated from the sensors, prior to any processing performed by the computing means. In a related embodiment, filters are also applied to signals during and after processing by the computing means (*i.e.*, filters applied prior to and during ICA algorithm operations, and/or applied to ICA operations output). In certain embodiments, linear or non-linear filtering is performed by an intelligence system of the subject invention.

[0043] Filters can be analog filters, such as those used for suppressing specific frequency components, which are well known in the art. Further, digital filters are also contemplated for use in the subject monitoring system. In certain embodiments, digital filtering operations are accomplished using a computing means, preferably a computer processor (*i.e.*, microprocessor or digital signal processor (DSP)).

[0044] By using filter(s), important signal components can be easily examined by filtering out undesired spectral components such as noise. Filtering operations that can be used, either alone or in combination, in extracting vital signal components include, but are not limited to, finite impulse response (FIR) filters and infinite impulse response (IIR) filters, such as band-pass filters, high pass filters, low pass filters, band-stop (or "notch") filters, and also to non-linear filters such as the median filter.

[0045] In certain embodiments, at least one band pass filter and/or low pass filter is applied to vital signals prior to processing with ICA algorithm operations. In related embodiments, band pass filters are applied to EMG/EHG signals or to ECG signals. In another embodiment, the FIR filter(s) is applied to ECG signals. In yet another embodiment, inverse filter(s), with or without band pass filter(s), are applied to post-processed vital signals to further refine clinical data provided by the vital signals (*i.e.*, maternal and fetal ECG).

[0046] In a preferred embodiment, the low pass filter is a butterworth filter. When a band pass filter is applied, the cut-off frequency is 100 Hz. Most preferably, a combination of band pass filter(s) and notch filter(s) is applied to vital signals, wherein the pass band is 0.16 Hz and 100 Hz, and the specific frequency of the notch filter is 60 Hz.

Hardware

[0047] Maternal-fetal vital signals (*i.e.*, ECG, and EHG signals) obtained in accordance with the subject invention are transmitted from the sensors to a computing means for signal processing. The computing means can also be responsible for maintenance of acquired data as well as the maintenance of the maternal-fetal monitoring system itself. The computing means can also detect and act upon user input via user interface means known to the skilled artisan (*i.e.*, keyboard, interactive graphical monitors).

[0048] In one embodiment, the computing means further comprises means for storing and means for outputting processed data. The computing means includes any digital instrumentation capable of processing signals from the sensors of the invention (*i.e.*, ECG signals). Such digital instrumentation, as understood by the skilled artisan, can process

communicated signals by applying algorithm and filter operations of the subject invention. Preferably, the digital instrumentation is a microprocessor, a personal desktop computer, a laptop, and/or a portable palm device. The computing means can be general purpose or application specific.

[0049] The subject invention can be practiced in a variety of situations. The computing means can directly or remotely connect to a central office or health care center. In one embodiment, the subject invention is practiced directly in an office or hospital. In another embodiment, the subject invention is practiced in a remote setting, for example, personal residences, mobile clinics, vessels at sea, rural villages and towns without direct access to healthcare, and ambulances, wherein the patient is located some distance from the physician.

[0050] In a related embodiment, the computing means is a custom, portable design and can be carried or attached to the patient in a manner similar to other portable electronic devices such as a portable radio, or interwoven in the patient clothing as a wearable computer.

[0051] Referring to Figure 3, the computing means can contain at least one user-interface device including, but not limited to, a keyboard **10**, stylus **12**, microphone **14**, mouse **16**, speaker **18**, monitor **20**, and printer **22**. Additional user-interface devices contemplated herein include touch screens, strip recorders, joysticks, and rollerballs.

[0052] Preferably, the computing means comprises a central processing unit (CPU) **30** having sufficient processing power to perform algorithm operations in accordance with the subject invention. The algorithm operations **36**, including the filtering operations **34** and **38**, can be embodied in the form of computer processor usable media, such as floppy diskettes, CD-ROMS, zip drives, non-volatile memory, or any other computer-readable storage medium, wherein the computer program code is loaded into and executed by the computing means. Optionally, the operational algorithms of the subject invention can be programmed directly onto the CPU using any appropriate programming language, preferably using the C programming language.

[0053] In certain embodiments, the computing means comprises a memory capacity sufficiently large to perform algorithm operations in accordance with the subject invention. The memory capacity of the invention can support loading a computer program code via a computer-readable storage media, wherein the program contains the source code to perform the operational algorithms **36** of the subject invention. Optionally, the memory capacity can support directly programming the CPU to perform the operational algorithms of the subject invention. A standard bus configuration can transmit data between the CPU, memory, ports and any communication devices.

[0054] In addition, as understood by the skilled artisan, the memory capacity of the computing means can be expanded with additional hardware and with saving data directly onto external mediums including, for example, without limitation, floppy diskettes, zip drives, non-volatile memory and CD-ROMs.

[0055] As described above, the computing means can include an A/D converter to translate analog signals into digital signals **32** (*i.e.*, an analog/digital card). The A/D converter preferably readies the signals for further processing according to the subject invention. Additional filtering steps may precede any algorithmic operations of the invention.

[0056] The computing means can further include the necessary hardware and software to convert processed signals into an output form **40** readily accessible by the trained physician, nurse practitioner, midwife, or technician. For example, without limitation, an audio device **42** in conjunction with audio speakers **18** can convert and play a processed fetal heartbeat into an audio signal, and/or a graphical interface **44** can display ECG signals in a graphical form on a monitor **20** and/or printer **22**. Further, the computing means can also include the necessary software and hardware to receive, route and transfer data to a remote location.

[0057] In one embodiment as disclosed, the patient is hospitalized, and clinical data generated by a computing means is transmitted to a central location, for example, a monitoring station located in a maternity ward, or to a specialized physician located in a different locale.

[0058] In another embodiment as disclosed, the patient is in remote communication with the health care provider. For example, patients can be located at personal residences, mobile clinics, vessels at sea, rural villages and towns without direct access to healthcare, and ambulances, and by using the maternal-fetal monitoring system of the invention, still provide clinical data to the health care provider. Advantageously, mobile stations, such as ambulances, and mobile clinics, can monitor maternal-fetal health by using a portable computing means of the subject invention when transporting and/or treating a patient.

[0059] To ensure patient privacy, security measures, such as encryption software and firewalls, can be employed. Optionally, clinical data can be transmitted as unprocessed or "raw" signal(s) and/or as processed signal(s). Advantageously, transmitting raw signals allows any software upgrades to occur at the remote location where a computing means is located. In addition, both historical clinical data and real-time clinical data can be transmitted.

[0060] Communication devices such as wireless interfaces, cable modems, satellite links, microwave relays, and traditional telephonic modems can transfer clinical data from a computing means to a healthcare provider via a network. Networks available for transmission of clinical data include, but are not limited to, local area networks, intranets and the open internet. A browser interface, for example, NETSCAPE NAVIGATOR or INTERNET EXPLORER, can be incorporated into communications software to view the transmitted data.

[0061] Advantageously, a browser or network interface is incorporated into the processing device to allow the user to

view the processed data in a graphical user interface device, for example, a monitor. The results of algorithm operations of the subject invention can be displayed in the form of the interactive graphics, such as those illustrated in Figures 4A-4F. The user, whether it be a physician, a nurse, a technician, or a patient, can indicate the placement of the electrodes on the graphical maternal abdomen. In one embodiment, a graphical representation of the maternal abdomen is provided (see Figure 4A) to track the location of the sensors (*i.e.*, electrodes) as well as to indicate to the user whether optimal fetal signals are being detected by the sensors.

Software

[0062] The maternal-fetal monitoring system of the subject invention can function in a real-time setting to continuously provide accurate clinical data to the user. In operation, as illustrated in Figure 5, maternal-fetal vital signals are captured by sensors **60** (raw signals) and input to an amplifier (*i.e.*, raw signals) **63**. Amplifier output is subsequently communicated to a variety of operational algorithms **36** for processing vital signals into clinical data and subsequent presentation of clinical data to the user **65**. Operational algorithms **36** can include, without limitation, fetal presentation operations **67**, ECG/heart rate operations **69**, and EHG operations **71**.

[0063] In certain instances, prior to vital signal processing, signals received from an amplifier are communicated to filter operations for each sensor channel. Raw signals extracted by sensors of the invention are a mixture of several sources, namely maternal-fetal vital signs (*i.e.*, maternal ECG, fetal ECG, EMG signals) and noise. In a preferred embodiment, each sensor channel is communicated to a corresponding band pass filter operation, which is accomplished on a computing means. A computer processor is used for filter operations as well as other processing functions.

[0064] The filtered signals are then followed by appropriate operations for obtaining desired clinical data (*i.e.*, ECG results (maternal and fetal); EHG results; a value to aid the user in assessing the quality of clinical data). Contemplated operations include, but are not limited to, ICA operations, EHG extraction operations; quality ("trust") factor operations; Pan Tompkins analysis operations; maternal-fetal channel determination operations; ECG waveform reconstruction operations; and fetal presentation operations.

1-Independent Component Analysis (ICA) Operations

[0065] Filtered sensor output is communicated to ICA operators for each specific sensor channel used for ECG collection. ICA operators of the invention are preferably implemented in real time on a computing means (*i.e.*, computer processor). The ICA operations place the filtered sensor output (*i.e.*, mixture of signals from several sources - maternal, fetal and noise) into estimated independent components. In one embodiment, ICA operations are capable of calculating the estimated fetal ECG, estimated maternal ECG, and estimations of other noises in the filtered sensor output.

[0066] A variety of algorithms, known to the skilled artisan, are available for use in ICA operations of the subject invention. ICA (or blind source separation - BSS) algorithmic operations contemplated for use in ICA operations of the subject invention include, but are not limited to, Infomax ICA operations (Bell, A. and T. Sejnowski, "An Information-Maximization Approach to Blind Separation and Blind Deconvolution," *Neural Computation*, 7:1129-1159 (1995)); minimum mutual information operations (Comon, P., "Independent Component Analysis, A New Concept?" *Signal Processing*, 36(3):287-314 (1994)); maximum entropy and minimum mutual information operations (Yang, H. and S. Amari, "Adaptive Online Learning Algorithms for Blind Separation: Maximum Entropy and Minimum Mutual Information," *Neural Computation*, 9:1467-1482 (1997)); and Mermaid ICA operations (Hild, K. et al., "Blind Source Separation Using Renyi's Mutual Information," *IEEE Signal Processing Letters*, 8(6):174-176(2001)).

[0067] In a preferred embodiment as disclosed, a Mermaid ICA algorithm is used in ICA operations. As known to the skilled artisan, a Mermaid ICA algorithm determines separate sources by minimizing the output mutual information. In one embodiment as disclosed, the Mermaid ICA algorithm uses Renyi's entropy to estimate mutual information.

[0068] In certain embodiments, to simplify the computation of the gradient, a Mermaid ICA algorithm first projects the sources onto an orthonormal (whitened) space and then rotates these projections into a space of minimal mutual information. The projection is done with the well known Principal Component Analysis method. The rotation is done by adaptively updating the Givens angles. This update is done in an online manner by minimizing the mutual information between the outputs of the ICA algorithm.

[0069] The optimization steps are as follows: (1) initializing Givens angles (to all zeros or randomly); (2) computing the whitening matrix as prescribed using all samples in off-line separation/updating the whitening matrix using an adaptive principle components algorithm (PCA) in on-line; (3) using in off-line separation the batch gradient obtained by direct derivation of the optimal separation matrix parameters of the vector of Givens rotation angles, which is computed using all available samples; or, using in on-line separation, the stochastic gradient; and (4) updating the Givens rotation angles using the steepest descent. According to the subject invention, the use of a Mermaid ICA algorithm for ICA operations results in timely and accurate output.

2-Pan Tompkins Operations

[0070] At the output of ICA operations, Pan Tompkins operations are performed on a computing means (*i.e.*, computer processor). Pan Tompkins operations are based in part on a known, standard algorithm (the Pan Tompkins algorithm).

[0071] In one example, the frequency bands of the Pan Tompkins algorithm are increased to higher frequencies and the lengths of the filters have been decreased. In a preferred embodiment, the following parameters of the standard Pan Tompkins algorithm are changed to fit the frequency range of fetal ECGs: (1) a band-pass filter; (2) a differentiation step (or function); and (3) a moving average step (function). More preferably, the parameters of the standard Pan Tompkins algorithm include the following: (1) a butterworth band-pass filter of order 6 and of pass band between 5 and 35 HZ is used; (2) a differentiation step of 5 point derivatives is used; (3) a moving average step following the squaring step uses a 20 point window.

[0072] The Pan Tompkins operations enable the detection of QRS complex peaks in the estimated maternal and fetal ECG signals (outputs of the ICA algorithm). QRS complex location is used in calculating specific clinical data, namely fetal heart rate data.

[0073] In a related embodiment, Pan Tompkins operators perform computational analyses to provide clinical data such as RR intervals (defined herein as the time in seconds between 2 consecutive QRS peaks); instantaneous or beat to beat heart rate (HR)(60/RR); average HR, HR variance (which can be updated beat by beat); as well as estimated numbers of false positive and false negative QRS complexes. This clinical data (number of false positives, false negatives, *etc.*) can be input to maternal-fetal channel determination operators and/or quality ("trust") factor operators to determine which output channel is the fetal ECG and to determine the quality of the signal, respectively.

[0074] Preferably a false positive peak is estimated to be present when the RR interval between the previous peak and the present one is less than 70% of the average of the 5 previous RR intervals. Further, preferably a false negative is estimated when the RR interval between the previous peak and the present one is greater than 130% of the average of the 5 previous RR intervals. Preferably, the average HR, HR variance, and number of false positive and false negative are calculated every 4 seconds.

3-Quality ("Trust") Factor Operations

[0075] In current monitoring systems, the signal separation performance cannot be directly measured because the actual original signals are not known. In contrast, the subject application enables determination of the quality of the separated signals (maternal versus fetal vital signals). In one embodiment of the invention, the quality of the ECG separation can be approximated by determining the properties of the ECG signals themselves. High quality ECG signals have high signal to noise ratios, clearly visible waveform characteristics typical of ECG waveforms, such as the P, Q, R, S, and T waves, and timing that is representative of the actual electro-mechanical beating of the heart. According to the subject invention, poor quality of signal separation indicates a great deal of noise whereas best quality of signal separation indicates any signal separation that is better than noise. For example, a quality of 0 is completely noise, a quality of 5 implies that the QRS waveform is clearly visible, repeatable, and much above the noise, and a quality of 7-10 implies that the P and T waves are visible.

[0076] The quality of the estimated fetal HR calculated from the fetal ECG and the quality of the fetal ECG signal itself, as extracted using the monitoring system of the subject invention, are directly related to the quality of the separation algorithm operations. There is currently no existing criterion for measuring the performance of separation algorithm (*i.e.*, ICA or BSS) operations in environments where the mixing matrix is unknown (*i.e.*, real data). According to the subject invention, a mechanism suitable for comparing the quality of separation algorithm operation performance on real data is based on an end-to-end system criterion (*i.e.*, in terms of the real goals of the system).

[0077] Similarly, an EHG quality assessment (or trust factor) can be derived from the processed EHG signal based upon input variables corresponding to features that are characteristic of fetal or maternal EHG signals. In a preferred embodiment as disclosed, the EHG quality assessment would be based on kurtosis, skewness, and the frequency components of the EHG signal. The kurtosis for the EHG should be approximately 8-10 for a 10-minute window. Skewness, a measure of symmetry, should be small indicating a symmetric EHG waveform. The EHG signal is also expected to have larger frequency components in the 0.1 to 0.5 Hz range.

[0078] Accordingly, a quality (or trust) factor (hereinafter referred to as "TF") can be provided using a TF operator of the subject invention, wherein the TF is based on intrinsic properties of the fetal ECG, HR, and/or EHG, and is used to enable the user to quantify signal separation success, automatic recognition of the maternal and fetal channels, and fetal ECG quality (*i.e.*, from 0 (no separation, low quality) to 10). TF operations are performed on the output of Pan Tompkins algorithm operations and on the output of the ICA algorithm, described above, to provide to the user a numerical representation of the quality of the fetal ECG and heart rate values monitored using the system of the invention, which is useful in making diagnostic decisions.

[0079] TF operations include the calculating for each signal at least one continuous probability function with at least

one input variable. With the subject invention, these continuous probability functions, called Pf (fetal) and Pm (maternal), represent the probabilities that the output signal in question, found by the ICA algorithm, is respectively a fetal or maternal ECG and its corresponding HR, found by correlation and Pan Tompkins.

[0080] Preferably, the probability function is a Gaussian function. This simple mathematical form describes the probability of encountering any given error. As well understood by the skilled artisan, the Gaussian distribution has two free parameters per dimension: the mean and the standard deviation. These parameters (*i.e.*, means and variances for each variable) can be fixed or variable. In one embodiment, these parameters can be determined individually or from a sample population.

[0081] Preferably, Pf and Pm consists of one or more of the following input variables corresponding to features that are characteristic of fetal or maternal ECG signals, respectively. These variables are compared to ideal values found for clean fetal or maternal ECG signals, or are compared to a combination of past values updated every 4 seconds. Preferably, these input variables include the following:

1. calculation of the estimated fetal heart rate with the autocorrelation function;
2. calculation of the estimated fetal heart rate with the Pan-Tompkins algorithm;
3. variance of the estimated fetal heart rate (from Pan Tompkins algorithm);
4. number of False Positives from Pan Tompkins algorithm;
5. number of False Negatives from Pan Tompkins algorithm;
6. the amplitude of the estimated fetal QRS peaks;
7. the ratio of the autocorrelation peak versus the variance of the autocorrelation function;
8. the sparsity of the estimated fetal ECG signal; and
9. mutual information. Mutual Information is calculated and minimized between the outputs of the ICA algorithm. The minimum value reached for a certain data set represents the quality of the separation and therefore can be used to determined separation quality.

[0082] In a preferred embodiment of the ECG trust factor, Pf and Pm have eight (8) input variables corresponding to features that are characteristic of fetal or maternal ECG signals, respectively.

[0083] Any one or combination of these input variables can be provided using processes as described below.

a) First, the average HR is calculated from the Pan Tompkins algorithm. For example, the average HR is the median value of the instantaneous HRs found by the Pan Tompkins operations during 4 seconds. For the calculation of Pf, this average HR is compared to a combination of past values of the average fetal HR, hereinafter called FHRav. FHRav is initialized for all the patients to a value calculated from a sample patient population. By way of example, for a sample patient population of 100 patients, the average FHR was determined to be 145 ± 35 bpm (beats per minute) with a variance of 20 ± 20 . This value is then updated every 4 seconds, depending on the x previous FHRs found, x being calculated as a function of the trust factor, as described in the following formula:

$$FHR_{av} = \frac{TF}{10} \times FHR + \frac{10 - TF}{10} \times FHR_{av} .$$

When the extracted signal quality is very high, the trust factor is very high and FHRav tends to be equal to the currently found FHR. Likewise, when the trust factor is low, the current FHR is not trustworthy, so a longer term average is used. The HRs found at the end of the Pan Tompkins algorithm are compared to FHRav in the calculation of Pf. The closer the HR is to this value, the more probable the signal is the FECG.

For the calculation of Pm, the HR found is compared to the value of the maternal Heart rate (called MHRav) found by a correlation operation applied on the raw data. The average MHR and its variance can be calculated for each patient because signals corresponding to the maternal channel are easily extracted due to a high maternal influence in sensed signals. For example, unfiltered sensor signals can be passed through an autocorrelation function known to the skilled artisan, wherein overlapping windows of data are correlated to obtain the evolution of the heart rate over a selected period of time. For each autocorrelation signal, the highest peaks corresponding to ECG periodicity are detected and translated to a heart rate, which represents the average MHR, thus allowing for the calculation of the average MHR variance.

Preferably, an autocorrelation is performed on the signals closest to the maternal heart (typically RA, LA and v1, see Figure 9) because these have the strongest maternal influence. A detection algorithm gives the location of the highest peak (beyond the DC offset) and therefore the average maternal RR interval and the average maternal heart rate. The three channels are then combined using a median function to prevent MHR errors caused if one electrode is disconnected or if any kind of problem arises on one or two electrodes.

b) The estimated variance of the HR is compared to a fixed value corresponding to the variance of the FHR/MHR found on a sample population. Preferably, the variance of the HR is compared to 25 in the calculation of Pf and to 4 in the calculation of Pm.

c) Next, the average amplitude of the detected QRS peaks in the output of ICA signal is calculated. The higher the amplitude of the peaks, the more probable the signal is an ECG signal.

d) An estimation of the number of correct beats not detected (false negative - FN); and an estimation of the number of incorrect beats detected (false positive - FP) is also computed from the peaks picked by the Pan Tompkins algorithm. The smaller these numbers are, the more probable the signal is an ECG signal. In a preferred embodiment, acceptable levels of FN and FP are less than 10%.

[0084] Also at the end of the ICA algorithm an autocorrelation is performed on the 4-seconds signals. For example, in the preferred embodiment where there are eight input variables, an autocorrelation is performed on eight 4-second signals. For each autocorrelation signal, a peak detection algorithm is performed to determine the highest non-DC peak. For an ECG signal, this peak corresponds to the average RR interval during the 4 second period, and therefore to the average HR (60/RR) during this 4 seconds period. From this autocorrelation method, several parameters are computed for the signals and serve as input to the probability functions:

1. The average HR (which can be determined by using the autocorrelation method described above). If the signal in question is not an ECG signal, this value is not representative of a HR. The closer this HR value is to the previous ECG HR value, the higher the TF will be. The HR is compared to FHRav in the calculation of Pf and to MHRav in the calculation of Pm.

2. The variance of the autocorrelation in between peaks. If the noise level in the signal is low, this value will be low. The lower this value is the higher the trust factor will be,

3. The amplitude of the peak in the autocorrelation function is compared with the variance of the autocorrelation function. The higher this ratio is the higher the TF will be.

[0085] Since the ECG signal is characterized by a QRS spike that is significantly larger than the rest of the signal, the sparsity of the ICA output signal is also used as a criterion to determine if it is an ECG signal. The percentage of signal data-points that are less than half of the peak value will be very large in an ECG signal, therefore this parameter is entered into the probability equation.

[0086] Another preferred measure of sparsity is Kurtosis. Kurtosis is defined as the normalized fourth central moment

of a distribution X: $kurtosis(X) = \frac{E[(X - \mu)^4]}{\sigma^4}$ where μ is the mean and σ the standard deviation of the distribution X. ECG signals typically have a kurtosis much greater than 4 and the noise signals typically have a kurtosis value close to 3 (the kurtosis of the Gaussian distribution). Experimentally, it was verified that for a signal to noise ratio (SNR) greater than 4dB, FECG and MECG can be clearly identified only by using the kurtosis of the signal.

[0087] Mutual Information is calculated and minimized between the outputs of the ICA algorithm. The minimum value reached for a certain data set represents the quality of the separation and therefore can be used to determine separation quality.

[0088] In the preferred embodiment, an additional test is performed after the Pan-Tompkins algorithm. In the case where the MHR and the FHR are very close, it is desirable to be able to distinguish the fetal ECG (FECG) and the maternal ECG (MECG) (and therefore the FHR and the MHR). A precise value for the MHR is easy to determine from the raw signal, and therefore the MECG at the output of the ICA algorithm is easy to recognize. From the MECGs, the Pan-Tompkins algorithm gives us the location of the MECG QRS peaks. To detect the fetal channel, the signals that have their QRS peaks at the same location (within a few points range) as the MECG QRS peaks are eliminated. Pf is brought to 0 for these signals.

[0089] TF operation in accordance with the subject invention provides the user with a means for assessing the performance and reliability of ICA operations output.

[0090] In one embodiment, the probability functions for a specific channel (kChan) are defined by the following mathematical and operational relationship: The associated Gaussian distribution curve is provided in Figure 6.

$$Pm^1 = e^{-0.5\left\{\left(\frac{HR1 - MHRav}{10}\right)^2 + \left(\frac{HRvar1 - 4}{10}\right)^2 + \left(\frac{AmpPeak - 10}{10}\right)^2 + \left(\frac{FN + FP}{10}\right)^2\right\}}$$

$$Pf^1 = e^{-0.5\left\{\left(\frac{HR1 - FHRav}{20}\right)^2 + \left(\frac{HRvar1 - 25}{20}\right)^2 + \left(\frac{AmpPeak - 8}{10}\right)^2 + \left(\frac{FN + FP}{10}\right)^2\right\}}$$

$$Pm^2 = e^{-\left(\frac{HR2 - MHRav}{\sqrt{2} \times 10}\right)^2 - \left(\frac{sparsity - 750}{\sqrt{2} \times 10}\right)^2} \frac{1}{2} \log(1 + 0.3r)$$

$$Pf^2 = e^{-\left(\frac{HR2 - FHRav}{\sqrt{2} \times 10}\right)^2 - \left(\frac{sparsity - 700}{\sqrt{2} \times 10}\right)^2} \frac{1}{2} \log(1 + 0.3r)$$

$$Pm = \text{Max}(Pm^1, Pm^2)$$

$$Pf = \text{Max}(Pf^1, Pf^2)$$

where:

e is the exponential operator;

HR1 is the heart rate calculated for each sensor channel during Pan Tompkins operations;

HR2 is the heart rate calculated for each sensor channel during the autocorrelation operations;

MHRav is the average maternal heart rate;

FHRav is the average fetal heart rate;

HRvar1 is the variance in HR;

FN is the estimated percentage of number of correct beats not detected;

FP is the estimated percentage of number of incorrect beats detected;

AmpPeak is the amplitude of the ECG QRS peaks;

sparsity is the number of points in the signal that are situated below 50% of the maximum (measure of the sparsity of the signal); and

r is the ratio between the amplitude of non-DC peak in the autocorrelation function; and the variance of the autocorrelation function.

[0091] In another embodiment, the input parameters are used to create membership functions based on the principles of fuzzy logic. Each parameter is compared to the expected value of the parameter and the membership function determines the probability that this parameter is consistent with the appropriate ECG signal. An example of the membership function for the Kurtosis parameter is:

$$Pf_k(x) = e^{-0.5 \frac{(x-8.1)^2}{1.8^2}}$$

$$Pm_1(x) = e^{-0.5 \frac{(x-22.9)^2}{8^2}}$$

[0092] One or more of these membership functions are then combined to create an overall probability for the selection/quality assessment of each channel. This combination can be done in multiple methods, but in this embodiment

one of the standard fuzzy logic techniques is used: $Pf = \min_i (Pf_i)$ and $Pm = \min_i (Pm_i)$, $i=1,2,3,\dots$

[0093] According to the subject invention, at the output of the ICA algorithm and Pan Tompkins algorithm operations, TF operations are performed on estimated signal results. TF operations include computing the probabilities for Pf and Pm, see Figure 6; and comparing the two probability values to classify whether the signal result is a maternal signal (i.e., maternal ECG), a fetal signal (i.e., fetal ECG), or other signal such as noise.

[0094] In certain embodiments, a TF is computed by truncating the value of 10 times the highest probability Pf. It

ranges from 0 to 10 (where 10 corresponds to a probability of 1). 0 is the worst case where the signal is very unlikely to be a fetal ECG and is most-likely noise. 10 is the best case where the fetal ECG is well detected and the value of the heart rate that is calculated using Pan Tompkins operations is an accurate value.

4-Maternal-Fetal Channel Determination Operations

[0095] The output signals of ICA operators are generally of arbitrary scale and order. In addition, as the signal changes, the location of the fetal signal channel is likely to change as well (*i.e.*, during contractions, the contraction signals become larger and produce different overall signal characteristics, both raw and separated). Thus, detecting which channels are maternal ECG, fetal ECG, and noise is beneficial to the user. Currently, channel classification is a complex task normally performed manually by skilled clinicians. The present disclosure advantageously provides automatic, real-time classification of maternal and fetal output channels to enable appropriate processing algorithm operations, such as those described above, on desired signals.

[0096] Maternal-fetal channel determination operations are performed on the TF operator(s) output. TF operator(s) output is processed by maternal-fetal channel determination operator(s) to identify the highest Pm and Pf values, which corresponds to the probability of the signal being a maternal or fetal signal channel, respectively. In a preferred embodiment, a signal is classified as a maternal signal when $P_m > P_f$ and $P_m > 0.7$. On the remaining signals (not classified as maternal signal), the signal with the highest Pf is classified as a fetal channel.

[0097] For cases where the FHR and the MHR are very close, the location of the QRS peaks is an important source of information to differentiate the two signals, since it is very unlikely that the fetal and maternal waveforms will be synchronized totally. The locations of the maternal QRS peaks are found in the electrodes closest to the maternal heart and with the Pan-Tompkins method, since the maternal ECG is very strong in these channels. At the output of the Pan-Tompkins algorithm, all the signals that have QRS peaks at the same location as the MEGG (with 20ms precision allowed) are eliminated by bringing their membership functions to zero.

5-EHG Extraction Operations

[0098] EHG extraction operations comprise (1) down-sample operator(s); (2) filtering operator(s); and (3) contraction detection operator(s). Any signals from sensors shown herein can be used in EHG extraction operations. In a preferred embodiment, signals from sensors located along the vertical midline of the maternal abdomen are input to EHG extraction operator(s).

[0099] Because EHG signal frequencies are often in a low frequency range (<5Hz), input signals received from an amplifier (and A/D converter) are communicated to down sample operator(s) to remove extraneous high-frequency information. For example, where signals from eight channels (see Figure 1, sensors **1a-1d**) are sampled originally at a frequency of 200 Hz, the down sample operator(s) reduces the sample rate to 20Hz. The down-sampling of the EHG is desired so as to reduce the volume of data to be processed by the computing means. In addition, at the output of the down-sample operator(s), a non linear operator can be performed on a combination of the down sampled signals. Preferably the nonlinear operator is the absolute value operator and the combination of channels is a pair wise difference:

$$1_{ab} = |1_a - 1_b|; \text{ and } 1_{cd} = |1_c - 1_d|.$$

[0100] These operator(s) output (absolute values of 1_{ab} and 1_{cd}) are communicated to filtering operator(s) to obtain the envelope of an EHG wave. Known digital filters can be used to perform EHG extraction/filtering operations. In one embodiment, a low pass Butterworth filter (*i.e.*, of order 4, having a cut off frequency 0.05Hz) is used to obtain the envelope or slow wave of at least one EHG wave.

[0101] Output from filtering operator(s) is input into contraction detection operator(s) to detect the beginning, end, duration and amplitude of a uterine muscle contraction. The contraction detection algorithm operation relies on identifying those segments in the EHG results that have values exceeding a particular threshold level for a specified duration. In order to determine the threshold, the contraction detection operator(s) analyze filtering operator(s) output signals using a specified time frame (or window). In one embodiment, filtering operator(s) output signals are analyzed by contraction detection operator(s) in 4 minute wide windows, with 1 minute shifts.

[0102] With every contraction detection operation, the signal samples (filtering operator(s) output) in a window are processed to obtain a basal tone and a threshold for normal versus contraction activity. To determine the threshold for detection of contraction changes, contraction detection operator(s) add 25% of the windowed signal range to the basal tone. Thus, the threshold for detection of contractions can change according to the signal level. A contraction can be recognized if the duration of an EMG result is greater than a set period of time (*i.e.*, 30 seconds) and the amplitude is greater than a percentage over the threshold value.

[0103] Contraction determination operations also include determining the intensity of contraction, which represents the number of spikes during every uterine contraction. Contraction intensity determination, as performed by contraction-determination operator(s), requires estimation of the timing parameters (starting time and duration) of the contraction signal. To determine contraction intensity, filtering operation output (high frequency signal, 1_{ab} and 1_{cd}) is input to another filter operator(s) to smooth (*i.e.*, remove high frequencies) the paired sensor signals. In one embodiment, the sensor signals are smoothed by a low pass Butterworth filter (4th order) with cut off frequency 0.4Hz. After "smoothing", the contraction determination operator(s) determine the number of positive peaks in each contraction. Only those contraction signal peaks having width greater than 2 seconds and amplitude greater than 25% of the contraction amplitude are analyzed.

[0104] Further, EHG extraction operation includes providing an EHG spectrogram and contraction curve. In one embodiment, the EHG spectrogram and contraction curve are plotted on a graphical user interface of the invention. In a preferred embodiment, the contraction curve is plotted below the fetal heart rate and maternal heart rate trace. It has been conjectured in the literature that contraction efficiency may be determined with appropriate analysis of the frequency content of the EHG signal. Moreover, spectral characteristics of the EHG curve may be able to be used to predict contraction efficiency and preterm labor. Accordingly, the present disclosure can convert EHG signals into values proportional to the pressure in the uterus (*i.e.*, IUPC) or directly to montevideo units, which to date has not been contemplated for monitoring systems. In further embodiments, the present disclosure utilizes neural network systems to convert EHG signals into Montevideo units.

[0105] The frequency content of the EHG, as typically shown in a spectrogram such as those illustrated in Figures 4B-4E, and other results provided by EHG extraction operations can aid the user in estimating or be used to determine contraction effectiveness, detecting false versus real labor (*i.e.*, useful in saving trips to the hospital for Braxton Hicks contractions), probability of vaginal delivery (or conversely, the need for a C-section), time to delivery, arrested descent, uterine rupture, and labor progress. As described above, this system could be used as a home monitoring system that not only continuously monitors fetal heart rate and ECG to detect fetal well-being, but also can be used to determine the difference between effective and non-effective contractions and false versus real labor.

[0106] In addition, the electrical signal from the abdomen (the EHG coupled with the EMG of abdominal muscles) could be used as a biofeedback mechanism to help direct maternal pushing effort during the second stage of labor. Such feedback may be particularly helpful when neuraxial analgesia has blunted sensation from the abdomen and perineum.

6-ECG Waveform Reconstruction Operations

[0107] It is well understood by the skilled clinician that heart defects can be detected by analyzing the different intervals and segments of ECGs. To determine normal ECG values for the fetal heart, which is applicable to fetal health (and heart health) during pregnancy or labor, more than the location of the heartbeat (the QRS segment) might be required. For example, the lower frequency attributes of the ECG signal, such as the P and T waves, can be useful in determining fetal heart standards, the early diagnosis of fetal heart defects, as well as establishing fetal health.

[0108] At the output of ICA algorithm operations, different signals may have been distorted by different filtering operations (*i.e.*, including preprocessing filtering with the amplifier). For example, ICA operations output often include fetal ECGs having P and T wave amplitudes comparable to the noise amplitude. This makes these waves difficult to detect. State of the art monitoring systems are unable to provide accurate fetal ECG waveforms (including lower frequency P and T waves) as well as to eliminate the high frequency noise and the base line wander. Normally, P and T wave frequencies are in the 1 to 5 Hz range for the maternal ECG and from 2 to 10 Hz for the fetal ECG. The base line wander is in the 0 to 3 Hz range and the high frequency noise, mainly due to the power line interference is approximately 60Hz.

[0109] Generally, the QRS peaks of ECG results are generally visible post ICA operations. However the fetal ECG signal output of ICA operations is commonly unrecognizable as an ECG signal by skilled physicians, who are accustomed to observing clean adult ECGs.

[0110] In certain embodiments of the monitoring system it is desirable to reconstruct a "reshaped" fetal ECG source. In one embodiment, at least one known filter is used to perform ECG waveform reconstruction operations on ICA operations output. In a related embodiment, an inverse filter and then a band pass filter are used by ECG waveform reconstruction operator(s) to reconstruct and highlight the different waves present in ECGs signal/ICA operations output (in particular fetal ECG signals) while removing high frequency noise and base line wander.

[0111] In a preferred embodiment, the following inverse filter operator (used in ECG waveform reconstruction operations) is defined by the inverse of the preprocessing filter: $H(z)=1/(1-0.99z^{-2})$.

[0112] The band pass filters used in ECG waveform reconstruction operations are FIR filters. In a preferred embodiment, for the maternal ECG signal, an FIR filter of order 40 and of band [2Hz, 50Hz] is used. For the fetal ECG signal, an FIR filter of order 30 and of band [5Hz, 50Hz] is used. The fetal ECG (and maternal ECG) waveforms can be plotted on a graded figure so as to enable the user to extract the different ECG intervals and segments that are useful in diagno-

sis/determining clinical strategy. Similarly, the ECG intervals can be calculated automatically by the processing means.

[0113] As described above, further embodiments provide a computing means that includes a storage means. The storage means can collect and/or display via the graphical user interface, ECG waveform reconstruction operations output (*i.e.*, ECG reconstructed waveforms having both P and T waves) as well as ICA operations output (*i.e.*, ECG with highlighted QRS spikes and P and T wave removal with other noises).

[0114] In certain embodiments, the present disclosure provides a software means for analyzing reconstructed ECGs, in particular, the fetal ECG. The reconstructed fetal ECG can be used to diagnose fetal acidosis and cardiac arrhythmias.

7-Operations for Determining Fetal Heart Electrical Influence in Different Sensors

[0115] During the first two trimesters of gestation, the fetoabdominal volume conductor can be considered as a homogenous volume conductor and therefore the closer the electrode is to the fetal heart the higher the amplitude of the fetal ECG signal from the sensor(s). The location of the sensors (*i.e.*, electrodes) corresponding to the highest coefficients provides the user with the location of the fetus in the uterus (low, high, right, left). The electrodes corresponding to the lowest coefficients can be moved to the region where the fetus is located in the abdomen to obtain raw signals with higher fetal influence (thus improving system performance).

[0116] From the 27th to the 37th weeks of gestation, a highly resistive layer surrounds the fetus: the vernix caseosa. Measurements confirm the model with a high resistivity layer (vernix) with 2 holes that are situated on the vertical axis. The two most probable pathways are the oronasal cavities situated over the head of the fetus and the umbilicus situated at the other end of the fetal torso. During this period the current flows are not transmitted homogeneously within the abdomen and the influence of the fetal ECG in the different sensor channels may not correspond to the fetal position in the uterus. However the user can still move the sensors, which have been determined to have low fetal influence using operations described below, to better locations on the maternal abdomen.

[0117] The ICA algorithm operations performance (*i.e.*, as quantified by TF output) depends on the quality of the raw signals and the relative amplitude of the fetal ECG in the raw data (prior to filtering operations). Accordingly, ICA algorithm operations output is a function of sensor position. The following operations for determining fetal heart electrical influence in sensors include the function of optimizing ICA algorithm operator(s) output.

[0118] Operations for determining fetal heart electrical influence in sensors of the invention include input-output matching for correlating ICA operator(s) output with raw sensor input (*i.e.*, non-filtered sensor input), see Figure 7. For example, at the output of ICA algorithm **73** and maternal-fetal channel determination **75** operations, the estimated fetal ECG signal **77** (or a projection of this fetal ECG signal based on the orientation of the electrodes and fetus) can be correlated **81** with the original, raw sensor signal channels **79**. The resultant correlation coefficients correspond to the influence of the fetal heart electrical influence in the different electrodes, and are provided to the user. Further, the correlation coefficients can be used in presenting to the user fetal position **83**.

[0119] Assuming the relationships between signals are linear, correlation techniques determine if a sensor signal output "resembles" another signal output, since these methods detect linear dependencies between signals. However, the linear dependency assumption is simplistic in the case of real data. Mutual information (MI) is a measure of dependencies (linear or non-linear) between signals. MI is null when the signals are independent. Thus, as the MI value increases, the strength of the dependency between the signals increases accordingly. With such cases, instead of simple correlation between the output of the ICA and the raw data, the input-output matching means can include calculating the mutual information value between the signals to find out the influence of the fetal signal output in each raw signal.

[0120] Alternatively, input-output matching means can be provided using non-linear matching methodologies. Neural network systems are non-linear adaptive systems that can detect non-linear dependencies between signals. Using a filtered version of the output of the ICA algorithm as a template and neural network, the influence of the fetal electrical activity in the different channels can be determined.

[0121] In certain situations, the ICA algorithm operator(s) output may not be optimal and/or the estimated fetal ECG may not be extracted. Although correlation of the estimated ECG signals and the raw signals can still be calculated, since the fetal channel may not contain any actual fetal ECG signal, the correlation coefficients may be skewed. To address this possibility, correlation is performed based on TF operations output. For example, since the trust factor operations output quantifies the performance of ICA algorithm operations, when TF operations output is lower than a set value, correlation calculation is not performed and the user is notified. In a preferred embodiment, a user is notified that correlation calculations will not be performed when TF operations output is lower than 2. The user can then change the position of the electrodes to obtain better signals (or correlation coefficients).

[0122] In one embodiment, the position of the electrodes is provided to the user on a graphical user interface. In the graphical user interface, a page is created to allow the user to display the placement of the electrodes on the maternal abdomen (*i.e.*, on a drawing). Where a set of electrode on a mesh is used, the position of the electrodes is always known and recognized by the computing means.

[0123] Using the correlation coefficients provided by operations for determining fetal electrical heart influence in the

sensors enables the user of the invention to fine tune the sensor placement for better signal positioning.

8-Fetal Presentation Operations

[0124] Fetal presentation impacts labor and delivery with the potential for prolongation of labor, increased pain and/or labor dystocia (inability to deliver vaginally) and possibly fetal distress and complications. While fetal presentation is normally determined by palpation of fetal parts through the maternal abdomen, accuracy depends on the skill of the examiner, as well as the girth of the patient. During labor the cervical examination can help identify the orientation of the fetal head (or presence of a different presenting part, e.g., foot or buttocks), but again depends on the skill of the examiner and the quality of the examination (dilation of the cervix, etc.). When doubt remains, ultrasound can usually identify the fetal presentation, if not the orientation of the presenting part (e.g., occiput direction). However, a routinely applied monitor that alerts the clinician to an abnormal presentation early on may reduce complications. For example, if a breech position is detected, either an external cephalic version (flipping the baby over) attempted, or elective cesarean delivery.

[0125] As known by the skilled artisan, different signals from different sensors placed on the maternal abdomen represent different projections of the fetal heart vector. As understood by the skilled clinician, different waveforms of fetal ECG signals have different shapes depending on the location/orientation of signal collection. Models of the fetal heart vector for different fetal presentations are created and the models are projected onto the 8 different signals (often called leads) to assess the quality of sensor placement. Templates of simulated fetal ECG waveforms corresponding to different fetal presentation in the uterus are then presented to an input-output matching means. In one embodiment, each template is correlated (or "matched") with the raw data at the location of the fetal QRS complex. Accurate fetal presentation is provided by the highest correlation coefficient.

[0126] As known to the skilled clinician, the heart possesses an underlying activation structure that serves the mechanical function of the heart as pump. The anatomy of the fetal heart differs from the adult heart in its mechanical functioning. As oxygen is supplied to the fetus by the placenta, the need for pumping blood through the lungs is not there. Postnatally, the left ventricle of the heart is pumping blood to the body and the right ventricle blood to the lungs. In the fetus both ventricles pump blood primarily to the body.

[0127] As illustrated in Figure 8, the maximum amplitude of the QRS complex for fetus and young children **90** is found when it points to the right-anterior inferior octant, whereas for adults it is rotated over 90 degrees and points to the left. For the P wave, in general, the same direction is observed in the fetal heart as in the adult heart **92**, pointing from the right to the left atrium. Data (as collected from newborns) show that it is likely that both P and T waves point in more or less the same direction and the R peak is more or less under an angle of 90 degrees with these other two. In this configuration, it is primarily the QRS complex that shows a different direction in the fetal case **90** when compared to the adult case **92**.

[0128] In one embodiment, it is assumed that the dipole model of the postnatal case resembles the prenatal case. The amplitude of the dipole representing both P and T wave is about one sixth of that of the QRS complex.

[0129] Depending on the fetal presentation as determined using operations described below, the fetal heart vector model has to be rotated. Then fetal presentation operator(s) project the different wave vectors onto the basis made by the different sensors (i.e., 8 electrodes of Figures 1 and 2) and a simulated fetal QRS complex for each electrode is obtained.

[0130] The electrodes (V_1 , V_2 , V_3 , V_4 , V_5 , V_6 , RA, and LA) are positioned on a maternal abdomen in Figure 9A using a mesh as seen in Figure 2. With a sensor-mesh, for pregnant women without heart problems or diseases, the shape of ECG waveforms should be similar to a template of simulated maternal waveforms, as long as the sensor positions remain unchanged. An example of a model for vertex presentation using the electrodes of Figure 9A is provided in Figure 9B. Figure 10 shows maternal simulated ECG waveforms for each electrode **100** in comparison against the actual, collected waveforms for each electrode **102**.

[0131] As described above, fetal ECG waveforms depend on the fetal presentation. Figure 11 shows the simulated fetal ECG waveforms **104** that should be obtained with the sensors placed in positions as described in Figure 9 when the fetus is in a normal OA position, head down, back in front. As illustrated in Figure 11, the collected ECG waveforms **106** substantially correspond to the simulated ECG waveforms **104**, wherein most of the differences can be attributed to a mixture of noise and maternal ECG.

[0132] A variety of templates corresponding to different fetal presentations can be provided and correlated with the collected waveforms and the template that provides the highest correlation coefficient corresponds to the estimated fetal presentation. The following are different templates of the invention, without limitation: Vertex (96.8% of pregnancies) as illustrated in Figure 12A; Breech (2.5% of pregnancies) as illustrated in Figure 12B; and Shoulder (0.4% of pregnancies) as illustrated in Figure 12C.

8-Intra-Uterine Pressure (IUP) Operations

[0133] Mechanical contractions are the manifestation of the cyclic polarization and depolarization of the uterine muscles. The spontaneous electrical discharge in the muscle from the uterus consists of intermittent bursts of spike discharges (action potentials), characterized by slow and fast waves. The slow wave is associated with the appearance of bursts while the fast wave determines the rate of firing of individual spikes within the bursts, and hence represents the contraction intensity. This electrical activity of the uterus increases the intrauterine pressure, thereby exerting force on the abdominal wall inducing mechanical contractions.

[0134] In certain embodiments, non-invasive and real-time estimation of intra-uterine pressure (IUP) can be determined using a means for estimating intra-uterine pressure. In certain embodiments, the means for estimating IUP includes software analysis of EHG extraction operations output. In other embodiments, a neural network (or other intelligence methods) system is provided to analyze EHG extraction operations output to determine IUP. A multi layer perceptron (MLP) can be used to estimate the IUP signal from the EHG, wherein the frequency information in the EHG from EHG extraction operations output is used. In a preferred embodiment, the MLP can be trained with an error that is weighted more heavily during contractions. In an additional embodiment, a signal derived from the EHG can be extracted that is not identical to the IUP signal, but yet contains clinically relevant information that can be used in lieu of the IUP signal.

[0135] An extracted signal derived from the EHG that contains clinically relevant information that can be used in lieu of the IUP signal (also referred to herein as the "IUP-like signal") can be used for a variety of purposes. For example, the IUP-like signal can be used to evaluate labor progression including evaluating contraction efficiency, the effectiveness of drugs used to induce labor, likelihood of labor dystocia, and/or to provide feedback as to the effectiveness of maternal expulsive efforts.

[0136] In a related embodiment, EHG extraction operations or IUP-like signals can be used during the post-partum period.

[0137] In one embodiment, the spectrogram of the EHG data set is computed over a window of 2000 samples and is divided into 18 different bands of frequencies ranging from 0-100 Hz. The average energy in every frequency bin (*i.e.*, 18 frequency bins) for the 8 channels is given as input to a neural network system (144 inputs). The window is shifted by 100 samples and the spectrogram computation is repeated. Thus the input to the MLP is the evolution of frequencies in the EHG over time.

[0138] In a preferred embodiment, the MLP has 18 input processing elements (PEs), 5 hidden layer PEs, and an output PE. Both the hidden and output layers have hyperbolic tangent non-linearities. As understood by skilled engineers in the field, the training stage on a neural network system is performed on a large number of data sets using an IUP catheter (IUPC), see Figure 13. The data is passed through the network repeatedly, and each time an error between the desired output of the network and the actual output of the network is computed. This error is used to adjust the parameters of the network to reduce the error. After repeated training passes, the error is minimized and the neural network is ready for use (typically, at this point, the system parameters are fixed). In the testing process, a set of data that was not used for training is passed through the system to ensure that the neural network has appropriately learned the task.

[0139] As understood by the skilled clinician, IUP is not homogenous in the uterus. Current usage of IUP catheters provides imprecise IUP measurement because IUP catheter output depends on the position of the catheter, the volume of amniotic fluid, and the position of the patient. Because the sensors of the subject invention can be placed at various locations on the abdomen, the pressure calculated by different sensors gives a different value for each sensor. In a preferred embodiment, a sensor is placed low on the abdomen, near the lower part of the uterus.

Example 1-Method for Personalizing a Sensor Mesh

[0140] A mesh of 20 electrodes was used to collect ECG signals. Each of the electrodes was selectively multiplexed into/out of the ICA and Pan Tompkins algorithm operations, depending on the quality of the signal and the TF for the fetal ECG output from Pan Tompkins operator(s). At the output of the ICA algorithm operator(s), the fetal ECG signal was correlated with 8 prefiltered raw signals. The 8 correlation coefficients correspond to the influence of the fetal heart in the different electrodes. The electrodes with the lowest correlation coefficients were switched out of the ICA/Pan Tompkins algorithm operations and other electrodes were switched into those operations to find the best set of electrodes for finding the fetal ECG.

[0141] By providing a method for personalizing a sensor mesh, the disclosure combines cumbersome individual sensor leads into a single cable, to enable the system to easily determine optimal locations on the mother for sensor placement, to obtain optimal raw sensor signals (*i.e.*, prior to filtration), and to improve patient comfort.

Example 2-Maternal-Fetal Monitoring System

[0142] As illustrated in Figure 14, a maternal-fetal monitoring system **200** is provided, wherein the system comprises an electrode mesh **202**, an amplifier, at least one filter **204**, and a processor for running an ICA algorithm **206**, preferably Mermaid, and calculating a Trust Factor **208**, to provide clinical information regarding maternal-fetal health. The electrode mesh has 10 electrodes, which are placed on the maternal abdomen. Electrodes having offset tabs that aid in eliminating noise artifacts are preferred. In this example, 1"1/4 Blue sensor Ag/AgCl electrodes are used. A 10 lead shielded cable is used to connect the electrodes to the amplifier.

[0143] The amplifier of the subject invention takes into account the fetal ECG, which typically is around 10 μ V to 50 μ V in amplitude. In a preferred embodiment, the amplifier of the invention is a high-resolution, low-noise unipolar amplifier in which all channels are referenced from a single electrode. With this amplifier, a driven right leg (DRL) circuit is utilized to actively suppress noise and improve the common mode rejection ratio (CMRR) of the amplifier. The following is a nonlimiting list of preferred amplifier specifications of the subject invention: (1) number of channels = 8; (2) gain is adjusted between 4,000 V/V and 10,000 V/V, but for practical purposes the gain is set to 4,500 V/V; (3) a pass band of 0.16 Hz and 100 Hz, with a 60 Hz notch filter; and (4) a CMRR of 80 dB.

[0144] The amplifier of this example has a 15-pin D-sub connector that interfaces with the 10-lead shielded ECG cable described above. The shielded cable aids in reducing any noise interference resultant from the 60 Hz transmitted from various power sources.

[0145] The amplifier output interfaces to an analog to digital converter, for example a 16-bit PCMCIA A/D card. The A/D converter sends the data to a processor that enables recordation and storage of raw ECG signals prior to processing. The collected raw signals are a mixture of several sources that are theoretically independent: the maternal ECG, the fetal ECG, EMG signals and other noise sources. Onboard the amplifier system is an isolated power converter that protects the patient from high leakage currents.

[0146] At specific time intervals, preferably every 4 seconds, the channels corresponding to VI and V2, V3 and V4 are combined by the processor and passed through a series of band pass filters **204**, **210** to obtain an EHG spectrogram study and a contraction curve. These curves are plotted on a graphical user interface (GUI) **212** for the 2 leads VI-V2 and V3-V4. The contraction curve is plotted below the FHR, MHR trace. The spectral characteristics of the EHG curves can be utilized by the processor to predict contraction efficiency and preterm labor.

[0147] Also at specific time intervals, preferably every 4 seconds, raw signals from 8 channels are presented to a band pass filter **204**. On the first 3 channels corresponding to LA, RA and VI the maternal HR is computed on the 4 second segment of the data. The median of these 3 values is kept as the maternal HR.

[0148] A modified ICA algorithm **206** of the processor, preferably the MERMAID ICA algorithm, is then applied to the filtered signals from the electrodes. The output of the ICA algorithm is the estimated independent components, *i.e.* the estimated fetal ECG, maternal ECG, and other components. Generally, 2 to 3 signals are found as different projections of the maternal ECG, 1 or 2 signals are projections of the fetal ECG, and the other signals are noise, EHG, or other signals not of interest.

[0149] At those specific time intervals, preferably every 4 seconds, at the output of the ICA algorithm, in this instance the Mermaid ICA algorithm, several autocorrelation functions are computed on each output signal and a peak detection algorithm is computed to find the HR on this segment of data. On the same 8 signals, an adapted version of a Pan Tompkins QRS detection algorithm **214** is performed by the processor. The processor computes for each signal the probability P_m that the signal is a maternal signal. The signals that provide a P_m higher than 0.7 are stored by the processor as maternal signals. Then the probability P_f that the signal is a fetal signal is computed. The signal with the highest P_f is classified as the best fetal channel.

[0150] The processor derives the trust factor (TF) **208** by truncating the value of 10 times the highest remaining probability P_f . The TF **208** ranges from 0 to 10, with 10 corresponding to a probability of 1 that the detected fetal signal is actually the fetal ECG. 0 is the worst case where the heart rate that is found is certainly not the fetal heart rate. The trust factor also describes the quality of the fetal ECG signal since low variance and few FN and FP are characteristic of a clean ECG signal and are represented by a high TF. The processor saves and plots the FHR, MHR every 4 seconds on the graphical user interface (GUI). The trust factor can be displayed on the GUI **212** as well.

[0151] In a preferred embodiment, the GUI **212** includes an interface where the user positions the electrode on a drawing of a pregnant woman as they were placed on the patient. The electrode position is saved. Every electrode position change corresponds to a model of the fetal heart vector projection on the different leads for different fetal presentations: normal vertex, breech or lateral presentation. Templates of simulated fetal ECG waveforms corresponding to different fetal presentation in the uterus are thus provided. Every minute, each template is correlated **218** with the raw data at the location of the fetal QRS complex (found by the Pan Tompkins algorithm operations) and displays the fetal presentation that gives the highest correlation coefficient. In most cases, the fetal presentation is the vertex position (96%).

[0152] At the output of the ICA separation algorithm, the estimated fetal ECG signal is correlated **218** with the 8 channels of prefiltered raw signals. These 8 correlation coefficients correspond to the influence of the fetal heart electrical

influence in the different electrodes. They are shown on the GUI 212 interface as a fetal electrical influence mapping.

[0153] The selected fetal ECG is passed through reconstruction filters 220 to reconstruct the shape of the waveforms that have been distorted by all the previous filters applied. The reconstructed FECG is plotted on the GUI 218 below the maternal ECG. An averaged FECG is calculated and plotted on the GUI 212. The different waveform intervals are computed and shown on the GUI 212.

[0154] This entire system (with a minimal user interface) can easily be constructed in a small, compact monitor that can be worn on a belt, similar to an ECG Holter monitor (approximately the size of a cigarette pack). It could also be built into an existing hospital monitor to provide additional information or replace the existing ultrasound/tocodynamometer system. Thus the system can be used as a home monitoring system (compact size and telecommunications ability) or a hospital monitoring system.

Example 3-Comparison of Intra-Uterine Pressure Values Using a Neural Network of the present disclosure versus an Intra-Uterine Pressure Catheter (IUPC)

[0155] An intelligence system (*i.e.*, neural network system) has been trained to predict the IUP from the electrical signals obtained from the abdominal ECG electrodes (EHG). The network was trained with three different patients and can be used to create an estimated non-invasive measure of IUP in patients. Figures 15A-C show the output of the neural network and the IUPC signal for three different data sets A, B, and C. The mean squared error (MSE) and correlation coefficient (CorrCoef) for each data set are provided in Table 1. As can be seen most of the peaks in a commercially available IUP catheter signal are well captured by the neural network of the subject invention. The high correlation coefficient in test data further supports the fact that the network has learnt the relationship.

Table 1-Quantitative Comparison of Values from an MLP of the present disclosure

Data Set	Training		Testing	
	MSE	CorrCoef	MSE	CorrCoef
A	165.131266	0.804183	132.039448	0.810358
B	24.256377	0.914247	20.674292	0.941033
C	79.525224	0.704184	25.695268	0.842167

Example 4-Comparison of Contraction Characteristics Analyzed in Accordance with the Monitoring System of the present disclosure versus Commercially Available Contraction Monitor

[0156] The EHG extraction operation was applied to 6 different data sets, wherein each set was analyzed for their contraction characteristics and the results provided to the user. The observations for data set D is presented in detail in Tables 2 and 3, wherein observations from a commercially available EHG monitor (Corometrics) is provided in Table 2 and observations using the EHG extraction operations are provided in Table 3.

[0157] Figure 16 gives the contraction curves of both channels 1_{V1-V2} (EHG I) and 1_{V3-V4} (EHG II) (illustrations of electrode location provided in Figures 9A and 9B) along with the corometrics contraction curve. Note that here both contraction curves are normalized in order to take into account the disparity in amplitude of the signals. A further quantitative comparison between the normalized EHG and Corometrics is achieved by computing their mean squared error and correlation coefficient, see Tables 2 and 3.

Table 2-EHG results using Corometrics

N (CORO)	Start [h:min:sec]	Duration [h:min:sec]	Peak	Peak Location [h:min:sec]
1	00:00:00	00:00:41	48	00:00:08
2	00:01:44	00:00:42	36	00:01:55
3	00:04:06	00:00:51	46	00:04:26
4	00:06:14	00:00:52	46	00:06:40
5	00:08:33	00:00:49	51	00:08:49
6	00:10:50	00:00:51	48	00:11:07
7	00:12:52	00:00:53	51	00:13:15

EP 1 776 041 B1

(continued)

N (CORO)	Start [h:min:sec]	Duration [h:min:sec]	Peak	Peak Location [h:min:sec]
8	00:15:42	00:00:42	43	00:15:57
9	00:17:27	00:00:41	44	00:17:46
10	00:18:58	00:00:34	34	00:19:12
11	00:20:34	00:01:01	40	00:20:56
12	00:24:13	00:00:38	39	00:24:35
13	00:26:00	00:00:48	32	00:26:18
14	00:28:12	00:00:47	46	00:28:37
15	00:30:11	00:00:54	43	00:30:35
16	00:32:38	00:00:43	45	00:32:54
17	00:34:46	00:00:49	41	00:35:05
18	00:36:57	00:00:51	47	00:37:19
19	00:39:20	00:00:42	40	00:39:36
20	00:41:11	00:00:43	37	00:41:28

Table 3-EHG results using EHG extraction operations

N (EHG-II)	Start [h:min:sec]	Duration [h:min:sec]	Peak	Peak Location [h:min:sec]
1	00:00:01	00:00:32	2074.2	00:00:00
2	00:01:39	00:00:40	1994.1	00:01:59
3	00:04:05	00:00:42	2553.4	00:04:25
4	00:06:10	00:00:50	2573.1	00:06:33
5	00:08:29	00:00:38	2369.2	00:08:47
6	00:10:50	00:00:35	2188.3	00:11:07
7	00:12:50	00:00:43	4093.7	00:13:09
8	00:15:36	00:00:41	2408.1	00:15:55
9	00:17:27	00:00:40	3224.3	00:17:45
10	00:18:47	00:00:43	1584.2	00:19:11
11	00:20:36	00:00:46	2472.4	00:20:57
12	00:22:29	00:00:57	1853.9	00:22:54
13	00:23:48	00:01:00	2761.5	00:24:17
14	00:25:47	00:01:00	2369.7	00:26:10
15	00:28:04	00:01:11	2054.3	00:28:25
16	00:30:10	00:01:01	2167.1	00:30:31
17	00:32:13	00:01:07	1837.7	00:32:58
18	00:34:47	00:00:41	1885.9	00:35:05
19	00:36:56	00:00:46	2713.1	00:37:21
20	00:39:20	00:00:39	2953.8	00:39:40
21	00:41:11	00:00:43	2649.9	00:41:30

[0158] Figure 17 shows each contraction waveform along with their computed threshold. This figure also shows the detected contractions with small rectangles each having width corresponding to the particular contraction duration. Note that peak location is also marked in Figure 17. The starting time, duration, maximum amplitude and location of maximum for each contraction are estimated and are tabulated below. As can be seen from the table the starting time of each detected contraction in most cases precedes that of the Corometrics. This is entirely logical since the electrical excitation should precede the muscle contraction.

[0159] Figure 18 shows the time interval between successive contractions as observed by the monitoring system of the present disclosure as compared to a Corometrics monitoring system. Such data can be significant since the onset of delivery is marked by rigorous uterine activity with a decreasing time span between consecutive contractions. A further and final comparison of EHG contraction waveform with a commercially available Corometrics counterpart is carried out for their contraction consistency. The result is presented graphically on a grid, as illustrated in Figures 19A-D. Row and column numbers denote the consecutive contraction numbers detected by both Corometrics and EHG (Figures 19A-19B). Note that there are two channels of EHG data. An additional grid of the first channel of EHG versus the second channel is also given in Figure 19C. Perfect agreement between measured and predicted contractions corresponds to a diagonal pattern of values on the grid Figure 19D.

[0160] The present invention is defined by the appended claims.

Claims

1. A maternal-fetal monitoring System comprising:

- a) at least two surface sensors to receive a mixture of maternal and fetal vital signals; and
- b) a computing means configured to analyze the mixture of maternal and fetal vital signals from the sensors, said computing means comprising hardware and Software, wherein said Software comprises an independent component analysis function configured to separate maternal from fetal vital signals in real-time, and said Software is configured to enable automatic selection of maternal and fetal vital signals separated by the independent component analysis function,

wherein said Software further comprises a quality assessing function configured to establish the quality of the maternal and fetal vital signals separated by the independent component analysis function, wherein the quality assessment function is configured to utilize trust factor operations at the output of the independent component analysis function and wherein the trust factor operations are performed on estimated signal results and wherein the trust factor operations include computing a first continuous probability function (Pf) that the output signal is a fetal signal and a second continuous probability function (Pm) that the output signal is a maternal signal.

2. The maternal-fetal monitoring system of claim 1, wherein the first continuous probability function (Pf) and/or the second continuous probability function (Pm) consist of one or more of the following input variables:

- a) a calculation of the estimated fetal heart rate with the autocorrelation function;
- b) a calculation of the estimated fetal heart rate with the Pan-Tompkins algorithm;
- c) a variance of an estimated fetal heart rate;
- d) a number of False Positives from the Pan Tompkins algorithm;
- e) a number of False Negatives from the Pan Tompkins algorithm;
- f) an amplitude of the estimated fetal QRS peaks;
- g) a ratio of the autocorrelation peak versus the variance of the autocorrelation function;
- h) a sparsity of an estimated fetal ECG signal;
- i) mutual Information.

3. The maternal-fetal monitoring System of claim 1 or 2, wherein the first and second continuous probability functions (Pf and Pm) have eight input variables corresponding to features that are characteristic of fetal or maternal ECG Signals.

4. The maternal-fetal monitoring System of claim 1, wherein the quality assessing function is configured to establish the quality of maternal and fetal vital signals selected from the group consisting of: ECG, EHG, and HR.

5. The maternal-fetal monitoring System of claim 1, wherein said Software is configured to enable automatic selection of best quality maternal and fetal vital signals separated by the independent component analysis function.

6. The maternal-fetal monitoring System of claim 1, wherein the probability function(s) is a Gaussian function.
7. The maternal-fetal monitoring system of claim 1, wherein the sensors are provided on a mesh or vest.
- 5 8. The maternal-fetal monitoring system of claim 7, wherein the sensors are provided on a mesh or vest in a configuration allowing at least two sensors to be placed on the vertical mid-line of the maternal abdomen.
9. The maternal-fetal monitoring system of claim 1, wherein the Software further comprises an EHG extracting means configured to extract EHG.
- 10 10. The maternal-fetal monitoring system of claims 8 and 9, configured to receive the maternal and fetal vital signals from the sensors along the midline of the maternal abdomen as input into the EHG extracting means.
11. The maternal-fetal monitoring System of claim 9, wherein the Software further comprises a means for providing an EHG spectrogram, a contraction curve, and an estimation of intra-uterine pressure from the EHG extracting means.
- 15 12. The maternal-fetal monitoring system of claim 9, wherein the EHG extracting means comprises at least one down-sample operator for removing extraneous high-frequency information; at least one filtering operator to obtain an EHG wave envelope; and at least one contraction detection operator to detect beginning, end, duration, and amplitude of a uterine muscle contraction.
- 20 13. The maternal-fetal monitoring system of claim 9, wherein the EHG extracting means further comprises at least one intelligence system.
- 25 14. The maternal-fetal monitoring system of claim 13, wherein the intelligence system is selected from the group consisting of: artificial neural networks, fuzzy logic, evolutionary computation, knowledge-based Systems, optimal linear or nonlinear filters, and artificial intelligence.
15. The maternal-fetal monitoring system of claim 1, further comprising an amplifier for amplifying maternal and fetal vital signs extracted by the sensors.
- 30 16. The maternal-fetal monitoring system of claim 1, wherein the Software further comprises a means for detecting QRS complex peaks in the maternal and fetal vital signals.
- 35 17. The maternal-fetal monitoring system of claim 16, wherein the means for detecting QRS complex peaks comprises a band-pass filter; a differentiation function; and a moving average function.
18. The maternal-fetal monitoring System of claim 17, wherein the means for detecting QRS complex peaks comprises a butterworth band-pass filter, a differentiation function of 5 point derivatives, and a moving average function of a 20 point window.
- 40 19. The maternal-fetal monitoring System of claim 16, wherein the means for detecting QRS complex peaks in maternal and fetal vital signals is configured to provide clinical data selected from the group consisting of: RR intervals, instantaneous heart rate, beat to beat heart rate, average heart rate, heart rate variance, and estimated false positive and false negative QRS complexes.
- 45 20. The maternal-fetal monitoring System of claim 1, wherein the independent component analysis means is selected from the group consisting of blind source Separation operations; Infomax ICA operations; minimum mutual Information operations; maximum entropy and minimum mutual Information operations; and Mermaid ICA operations.
- 50 21. The maternal-fetal monitoring System of claim 1, wherein the independent component analysis means is configured to analyze maternal and fetal vital signals to provide clinical data selected from the group consisting of estimated fetal ECG and estimated maternal ECG.
- 55 22. The maternal-fetal monitoring System of claim 1, wherein the Software further comprises an auto-correlation means for processing the separated maternal and fetal vital signals.
23. The maternal-fetal monitoring System of claim 1, wherein the Software further comprises a means for automatically

determining the location of fetal vital signals and maternal vital signals.

24. The maternal-fetal monitoring System of claim 1, wherein the System is portable.

25. A method for monitoring maternal-fetal vital signals from a patient and fetus, comprising:

- a) providing a maternal-fetal monitoring System according to any of Claims 1 to 24,
- b) placing at least two surface sensors on the patient's abdomen to receive a mixture of maternal and fetal vital signals; and
- c) connecting the sensors to the computing means for analyzing the mixture of maternal and fetal vital signals from the sensors.

Patentansprüche

1. Mutter-Fötus-Überwachungssystem, umfassend:

- a) mindestens zwei Oberflächensensoren zum Empfangen einer Mischung aus mütterlichen und fötalen Vital-signalen; und
- b) ein Berechnungsmittel, das konfiguriert ist, um die Mischung aus mütterlichen und fötalen Vitalsignalen von den Sensoren zu analysieren, wobei das Berechnungsmittel Hardware und Software umfasst, wobei die Software eine unabhängige Komponentenanalysefunktion umfasst, die konfiguriert ist, um mütterliche und fötale Vitalsignale in Echtzeit zu trennen, und wobei die Software konfiguriert ist, um eine automatische Auswahl von mütterlichen und fötalen Vitalsignalen zu ermöglichen, die durch die unabhängige Komponentenanalysefunktion getrennt sind,

wobei die Software weiter eine Qualitätsbewertungsfunktion umfasst, die konfiguriert ist, um die Qualität der mütterlichen und fötalen Vitalsignale, die durch die unabhängige Komponentenanalysefunktion getrennt sind, zu bestimmen,

wobei die Qualitätsbewertungsfunktion konfiguriert ist, um Vertrauensfaktor-Operationen am Ausgang der unabhängigen Komponentenanalysefunktion zu nutzen, und

wobei die Vertrauensfaktor-Operationen an geschätzten Signalergebnissen durchgeführt werden und

wobei die Vertrauensfaktor-Operationen das Berechnen einer ersten kontinuierlichen Wahrscheinlichkeitsfunktion (Pf), dass das Ausgangssignal ein fötales Signal ist, und einer zweiten kontinuierlichen Wahrscheinlichkeitsfunktion (Pm), dass das Ausgangssignal ein mütterliches Signal ist, beinhalten.

2. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei die erste kontinuierliche Wahrscheinlichkeitsfunktion (Pf) und/oder die zweite kontinuierliche Wahrscheinlichkeitsfunktion (Pm) aus einer oder mehreren der folgenden Eingangsvariablen bestehen:

- a) einer Berechnung der geschätzten fötalen Herzfrequenz mit der Autokorrelationsfunktion;
- b) einer Berechnung der geschätzten fötalen Herzfrequenz mit dem Pan/Tompkins-Algorithmus;
- c) einer Varianz einer geschätzten fötalen Herzfrequenz;
- d) einer Anzahl von falsch positiven Ergebnissen vom Pan/Tompkins-Algorithmus;
- e) einer Anzahl von falsch negativen Ergebnissen vom Pan/Tompkins-Algorithmus;
- f) eine Amplitude der geschätzten fötalen QRS-Zacken;
- g) ein Verhältnis des Autokorrelations-Zacke im Vergleich zur Varianz der Autokorrelationsfunktion;
- h) eine geringe Dichte eines geschätzten fötalen EKG-Signals;
- i) gegenseitige Informationen.

3. Mutter-Fötus-Überwachungssystem nach Anspruch 1 oder 2, wobei die ersten und zweiten kontinuierlichen Wahrscheinlichkeitsfunktionen (Pf und Pm) acht Eingangsvariablen aufweisen, die Merkmalen entsprechen, die für fötale oder mütterliche EKG-Signale charakteristisch sind.

4. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei die Qualitätsbeurteilungsfunktion konfiguriert ist, um die Qualität der mütterlichen und fötalen Vitalsignale, ausgewählt aus der Gruppe bestehend aus: EKG, EHG und HR, zu bestimmen.

5. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei die Software konfiguriert ist, um eine automatische Auswahl von qualitativ hochwertigen fötalen und mütterlichen Vitalsignalen ermöglichen, die durch die unabhängige Komponentenanalysefunktion getrennt sind.
- 5 6. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei die Wahrscheinlichkeitsfunktion(en) eine Gaußfunktion ist/sind.
7. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei die Sensoren auf einem Netzgewebe oder einer Weste bereitgestellt sind.
- 10 8. Mutter-Fötus-Überwachungssystem nach Anspruch 7, wobei die Sensoren auf einem Netzgewebe oder einer Weste in einer Konfiguration bereitgestellt sind, die es erlaubt, mindestens zwei Sensoren auf der vertikalen Mittellinie des mütterlichen Bauches anzubringen.
- 15 9. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei die Software weiter ein EHG-Extraktionsmittel umfasst, das konfiguriert ist, um EHG zu extrahieren.
- 20 10. Mutter-Fötus-Überwachungssystem nach Anspruch 8 und 9, das konfiguriert ist, um die mütterlichen und fötalen Vitalsignale von den Sensoren entlang der Mittellinie des mütterlichen Abdomens als Eingabe in das EHG-Extraktionsmittel zu empfangen.
- 25 11. Mutter-Fötus-Überwachungssystem nach Anspruch 9, wobei die Software weiter ein Mittel zum Bereitstellen eines EHG-Spektrogramms, einer Kontraktionskurve und einer Schätzung des intrauterinen Drucks aus dem EHG-Extraktionsmittel umfasst.
- 30 12. Mutter-Fötus-Überwachungssystem nach Anspruch 9, wobei das EHG-Extraktionsmittel mindestens einen Downsampling-Operator zum Entfernen von Fremd-Hochfrequenzinformationen umfasst; mindestens einen Filter-Operator, um eine EHG-Wellenhülle zu erhalten; und mindestens einen Kontraktionserfassungs-Operator zum Erfassen von Beginn, Ende, Dauer und Amplitude einer Gebärmuttermuskelerkontraktion.
- 35 13. Mutter-Fötus-Überwachungssystem nach Anspruch 9, wobei das EHG-Extraktionsmittel weiter mindestens ein Intelligence-System umfasst.
- 40 14. Mutter-Fötus-Überwachungssystem nach Anspruch 13, wobei das Intelligence-System ausgewählt ist aus der Gruppe bestehend aus: künstlichen neuronalen Netzen, Fuzzy-Logik, evolutionärer Berechnung, wissensbasierten Systemen, optimalen linearen oder nichtlinearen Filtern und künstlicher Intelligenz.
- 45 15. Mutter-Fötus-Überwachungssystem nach Anspruch 1, weiter umfassend einen Verstärker zum Verstärken der durch die Sensoren extrahierten mütterlichen und fötalen Vitalparameter.
- 50 16. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei die Software weiter ein Mittel zum Erfassen von QRS-Komplex-Zacken in den mütterlichen und fötalen Vital-Signalen umfasst.
- 55 17. Mutter-Fötus-Überwachungssystem nach Anspruch 16, wobei das Mittel zum Erfassen von QRS-Komplex-Zacken einen Bandpassfilter; eine Differenzierungsfunktion; und eine gleitende Durchschnittsfunktion umfasst.
18. Mutter-Fötus-Überwachungssystem nach Anspruch 17, wobei das Mittel zum Erfassen von QRS-Komplex-Zacken einen Butterworth-Bandpassfilter, eine Differenzierungsfunktion von 5-Punkt-Derivaten und eine gleitende Durchschnittsfunktion eines 20-Punkt-Fensters umfasst.
19. Mutter-Fötus-Überwachungssystem nach Anspruch 16, wobei das Mittel zum Erfassen von QRS-Komplex-Zacken in mütterlichen und fötalen Vitalsignalen konfiguriert ist, um klinische Daten bereitzustellen, ausgewählt aus der Gruppe bestehend aus: RR-Intervalle, momentane Herzfrequenz, Beat-to-Beat-Herzfrequenz, durchschnittliche Herzfrequenz, Herzfrequenzvarianz und geschätzte falsch positive und falsch negative QRS-Komplexe.
20. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei das unabhängige Komponentenanalysemittel ausgewählt ist aus der Gruppe bestehend aus Blindenquellentrennungs-Operationen; Infomax-ICA-Operationen; minimale gegenseitige Informations-Operationen; maximale Entropie- und minimale gegenseitige Informations-Operationen;

und Sirenomelie-ICA-Operationen.

21. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei das unabhängigen Komponentenanalysemittel konfiguriert ist, um mütterliche und fötale Vitalsignale zu analysieren, um klinische Daten bereitzustellen, die aus der Gruppe ausgewählt sind, die aus geschätztem fötalen EKG und geschätztem mütterlichen EKG besteht.

22. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei die Software weiter ein Autokorrelationsmittel zum Verarbeiten der getrennten mütterlichen und fötalen Vitalsignale umfasst.

23. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei die Software weiter ein Mittel zum automatischen Bestimmen der Position von fötalen Vitalsignalen und mütterlichen Vitalsignalen umfasst.

24. Mutter-Fötus-Überwachungssystem nach Anspruch 1, wobei das System tragbar ist.

25. Verfahren zum Überwachen der mütterlichen/fötalen Vitalsignale von einer Patientin und einem Fötus, umfassend:

- a) Bereitstellen eines Mutter-Fötus-Überwachungssystems nach einem der Ansprüche 1 bis 24,
- b) Anbringen von mindestens zwei Oberflächensensoren am Bauch der Patientin, um eine Mischung aus mütterlichen und fötalen Vitalsignalen zu empfangen; und
- c) Verbinden der Sensoren mit den Berechnungsmitteln zum Analysieren der Mischung aus mütterlichen und fötalen Vitalsignalen von den Sensoren.

Revendications

1. Système de surveillance maternelle-foetale comprenant :

- a) au moins deux capteurs de surface pour recevoir un mélange de signaux vitaux maternels et foetaux ; et
- b) un moyen informatique configuré pour analyser le mélange de signaux vitaux maternels et foetaux venant des capteurs, ledit moyen informatique comprenant un matériel informatique et un logiciel, dans lequel ledit logiciel comprend une fonction d'analyse de composants indépendante configurée pour séparer les signaux vitaux maternels des signaux vitaux foetaux en temps réel et ledit logiciel est configuré pour permettre la sélection automatique de signaux vitaux maternels et foetaux séparés par la fonction d'analyse de composants indépendante,

dans lequel ledit logiciel comprend en outre une fonction d'évaluation de qualité configurée pour établir la qualité des signaux vitaux maternels et foetaux séparés par la fonction d'analyse de composants indépendante, dans lequel la fonction d'évaluation de qualité est configurée pour utiliser des opérations de facteur de confiance à la sortie de la fonction d'analyse de composants indépendante et dans lequel les opérations de facteur de confiance sont effectuées sur des résultats de signaux estimés et dans lequel les opérations de facteur de confiance incluent le calcul d'une première fonction de probabilité continue (Pf) que le signal de sortie est un signal foetal et d'une seconde fonction de probabilité continue (Pm) que le signal de sortie est un signal maternel.

2. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel la première fonction de probabilité continue (Pf) et/ou la seconde fonction de probabilité continue (Pm) sont constituées d'une ou plusieurs des variables d'entrée suivantes :

- a) un calcul de la fréquence cardiaque foetale estimée avec la fonction d'autocorrélation ;
- b) un calcul de la fréquence cardiaque foetale estimée avec l'algorithme de Pan-Tompkins ;
- c) une variance d'une fréquence cardiaque foetale estimée ;
- d) un nombre de faux positifs venant de l'algorithme de Pan-Tompkins ;
- e) un nombre de faux négatifs venant de l'algorithme de Pan-Tompkins ;
- f) une amplitude des pics QRS foetaux estimés ;
- g) un rapport du pic d'autocorrélation à la variance de la fonction d'autocorrélation ;
- h) une rareté d'un signal ECG foetal estimé ;
- i) des informations mutuelles.

3. Système de surveillance maternelle-foetale selon la revendication 1 ou 2, dans lequel la première et la seconde fonction de probabilité continue (Pf et Pm) ont huit variables d'entrée correspondant à des caractéristiques qui caractérisent les signaux ECG foetaux ou maternels.
- 5 4. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel la fonction d'évaluation de qualité est configurée pour établir la qualité de signaux vitaux maternels et foetaux choisis dans le groupe constitué des suivants : ECG, EHG et HR.
- 10 5. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel ledit logiciel est configuré pour permettre la sélection automatique des signaux vitaux maternels et foetaux de la meilleure qualité séparés par la fonction d'analyse de composants indépendante.
- 15 6. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel la ou les fonctions de probabilité est ou sont des fonctions gaussiennes.
7. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel les capteurs sont disposés sur un filet ou un gilet.
- 20 8. Système de surveillance maternelle-foetale selon la revendication 7, dans lequel les capteurs sont disposés sur un filet ou un gilet dans une configuration permettant de placer au moins deux capteurs sur la ligne centrale verticale du ventre maternel.
- 25 9. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel le logiciel comprend en outre un moyen d'extraction de EHG configuré pour extraire le EHG.
- 30 10. Système de surveillance maternelle-foetale selon les revendications 8 et 9, configuré pour recevoir les signaux vitaux maternels et foetaux des capteurs le long de la ligne centrale du ventre maternel comme entrée dans le moyen d'extraction de EHG.
- 35 11. Système de surveillance maternelle-foetale selon la revendication 9, dans lequel le logiciel comprend en outre un moyen pour fournir un spectrogramme EHG, une courbe de contraction et une estimation de la pression intra-utérine venant du moyen d'extraction de EHG.
- 40 12. Système de surveillance maternelle-foetale selon la revendication 9, dans lequel le moyen d'extraction de EHG comprend au moins un opérateur de sous-échantillonnage pour éliminer les informations étrangères de haute fréquence ; au moins un opérateur de filtration pour obtenir une enveloppe d'ondes EHG ; et au moins un opérateur de détection de contractions pour détecter le début, la fin, la durée et l'amplitude d'une contraction musculaire utérine.
- 45 13. Système de surveillance maternelle-foetale selon la revendication 9, dans lequel le moyen d'extraction de EHG comprend en outre au moins un système d'intelligence.
- 50 14. Système de surveillance maternelle-foetale selon la revendication 13, dans lequel le système d'intelligence est choisi dans le groupe constitué des suivants : réseaux neuraux artificiels, circuit de logique floue, calcul évolutionnaire, systèmes à base de connaissance, filtres linéaires ou non linéaires optimaux et intelligence artificielle.
- 55 15. Système de surveillance maternelle-foetale selon la revendication 1, comprenant en outre un amplificateur pour amplifier les signaux vitaux maternels et foetaux extraits par les capteurs.
16. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel le logiciel comprend en outre un moyen pour détecter des pics complexes QRS dans les signaux vitaux maternels et foetaux.
17. Système de surveillance maternelle-foetale selon la revendication 16, dans lequel le moyen de détection de pics complexes QRS comprend un filtre passe-bande ; une fonction de différenciation ; et une fonction de moyenne mobile.
18. Système de surveillance maternelle-foetale selon la revendication 17, dans lequel le moyen de détection de pics complexes QRS comprend un filtre passe-bande Butterworth, une fonction de différenciation de dérivés de 5 points et une fonction de moyenne mobile d'une fenêtre de 20 points.

19. Système de surveillance maternelle-foetale selon la revendication 16, dans lequel le moyen de détection de pics complexes QRS dans les signaux vitaux maternels et foetaux est configuré pour fournir des données cliniques choisies dans le groupe constitué des suivantes : intervalles RR, fréquence cardiaque instantanée, fréquence cardiaque battement par battement, fréquence cardiaque moyenne, variance de fréquence cardiaque et complexes faux positifs et faux négatifs QRS estimés.

20. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel le moyen d'analyse de composants indépendant est choisi dans le groupe constitué d'opérations de séparation de source aveugle ; d'opérations ICA Infomax ; d'opérations d'information mutuelles minimales ; d'opérations d'entropie maximale et d'opérations d'informations mutuelles minimales ; et d'opérations ICA Mermaid.

21. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel le moyen d'analyse de composants indépendant est configuré pour analyser des signaux vitaux maternels et foetaux afin de fournir des données cliniques choisies dans le groupe constitué d'un ECG foetal estimé et d'un ECG maternel estimé.

22. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel le logiciel comprend en outre un moyen d'autocorrélation pour traiter les signaux vitaux maternels et foetaux séparés.

23. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel le logiciel comprend en outre un moyen pour déterminer automatiquement l'emplacement de signaux vitaux foetaux et de signaux vitaux maternels.

24. Système de surveillance maternelle-foetale selon la revendication 1, dans lequel le système est portable.

25. Procédé de surveillance de signaux vitaux maternels-foetaux venant d'un patient et d'un fœtus, comprenant :

a) la fourniture d'un système de surveillance maternelle-foetale selon l'une quelconque des revendications 1 à 24, b) le placement d'au moins deux capteurs de surface sur le ventre du patient afin de recevoir un mélange de signaux vitaux maternels et foetaux ; et

c) la connexion des capteurs aux moyens informatiques pour analyser le mélange de signaux vitaux maternels et foetaux issus des capteurs.




FIG. 1




FIG. 2




FIG. 3

FIG. 4A

The diagram illustrates the placement of electrodes for fetal heart rate monitoring. It shows two views: 'Front' and 'Back'. In the 'Front' view, electrodes are labeled V1, V2, V3, V4, V5, V6, RA, and LA. In the 'Back' view, electrodes are labeled V1, V2, V3, V4, V5, V6, RA, and LA. A 'Standard Position' checkbox is present, along with 'Reset' and 'OK' buttons.

FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F

Cv In Test Made for Database C:\ETG-GRANT\DATA\ZTC\DATA-Bottanelli\Good Data\2003 Date 1 Jul 2003 Time 15:11																																																																																									
Raw	EHG frequencies	FEDG and MEFG	Electrodes location	FHR and Contraction	Patient Information																																																																																				
Data Collector Name:				☐ Tense																																																																																					
Parity #:	1000	TEPC (Y/N):		GA (wk/d):	40																																																																																				
Maternal Weight (lbs):	150	FSE (Y/N):		BSW (lb):																																																																																					
Membranes Intact (SRONAROM):	atom	Epithelial (Y/N) time of injection:		Gender (F/M):	F																																																																																				
Pilocine (Y/N) time of injection:	8	Other Medicines time of injection:		Fetal Position (Breech Normal left):																																																																																					
Diagnostic:		Other Dx:																																																																																							
Other Comments:																																																																																									
1505 pt moving																																																																																									
		OK																																																																																							
<table border="1"> <thead> <tr> <th colspan="2">Controls</th> <th colspan="2">ND Algorithms</th> <th colspan="2">Colometrics</th> </tr> </thead> <tbody> <tr> <td>0</td> <td></td> <td>IA 368</td> <td>V3 129</td> <td>FHR 136</td> <td>FHR variance 18.88</td> </tr> <tr> <td>Continue</td> <td></td> <td>RA 374</td> <td>V4 303</td> <td>Trust 5</td> <td>Mean Trust 5.932514</td> </tr> <tr> <td></td> <td></td> <td>V1 301</td> <td>V5 220</td> <td></td> <td></td> </tr> <tr> <td></td> <td></td> <td>V2 149</td> <td>V6 282</td> <td></td> <td></td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td>Fetal position:</td> <td></td> </tr> <tr> <td colspan="2"></td> <td colspan="2"></td> <td>Colometrics</td> <td></td> </tr> <tr> <td colspan="2"></td> <td colspan="2"></td> <td>FHR 137</td> <td></td> </tr> <tr> <td colspan="2"></td> <td colspan="2"></td> <td>ND/Colometrics 3978</td> <td></td> </tr> <tr> <td colspan="2"></td> <td colspan="2"></td> <td>FHR MSE</td> <td></td> </tr> <tr> <td colspan="2"></td> <td colspan="2"></td> <td>Uterine Act 16</td> <td></td> </tr> <tr> <td colspan="2"></td> <td colspan="2"></td> <td>Battery</td> <td></td> </tr> <tr> <td colspan="2"></td> <td colspan="2"></td> <td>Data OK</td> <td></td> </tr> <tr> <td colspan="2"></td> <td colspan="2"></td> <td>17:10:27</td> <td></td> </tr> </tbody> </table>						Controls		ND Algorithms		Colometrics		0		IA 368	V3 129	FHR 136	FHR variance 18.88	Continue		RA 374	V4 303	Trust 5	Mean Trust 5.932514			V1 301	V5 220					V2 149	V6 282							Fetal position:						Colometrics						FHR 137						ND/Colometrics 3978						FHR MSE						Uterine Act 16						Battery						Data OK						17:10:27	
Controls		ND Algorithms		Colometrics																																																																																					
0		IA 368	V3 129	FHR 136	FHR variance 18.88																																																																																				
Continue		RA 374	V4 303	Trust 5	Mean Trust 5.932514																																																																																				
		V1 301	V5 220																																																																																						
		V2 149	V6 282																																																																																						
				Fetal position:																																																																																					
				Colometrics																																																																																					
				FHR 137																																																																																					
				ND/Colometrics 3978																																																																																					
				FHR MSE																																																																																					
				Uterine Act 16																																																																																					
				Battery																																																																																					
				Data OK																																																																																					
				17:10:27																																																																																					




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9A




FIG. 9B




FIG. 10




FIG. 11



FIG. 12A



FIG. 12B



FIG. 12C





FIG. 13

FIG. 14

200






FIG. 15A




FIG. 15B




FIG. 15C




FIG. 16




FIG. 17




FIG. 18




FIG. 19A




FIG. 19B





FIG. 19C



EHG-II

FIG. 19D

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6594515 B [0008]
- US 6115624 A [0008]
- US 6058321 A [0008]
- US 5746212 A [0008]
- US 5184619 A [0008]
- US 4951680 A [0008]
- US 4437467 A [0008]
- US 4945917 A [0009]
- US 4781200 A [0009]
- US 5042499 A [0009]
- US 5209237 A [0009]
- US 5490515 A [0009]

Non-patent literature cited in the description

- Healthy People. National Vital Statistics System (NVSS), CDC, NCHS. Understanding and Improving Health, 2010 [0001]
- Centers for Disease Control and Prevention and Health Resources and Services Administration. U.S. Government Printing Office, November 2000 [0001]
- **WIDROW, B. et al.** Adaptive Noise Canceling: Principals and Applications. *Proc. IEEE*, December 1975, vol. 63 (12), 1692-1716 [0009]
- **ADAM, D. ; D. SHAVIT.** Complete Fetal ECG Morphology Recording by Synchronized Adaptive Filtration. *Med. & Biol. Eng. & Comput.*, July 1990, vol. 28, 287-292 [0009]
- **FERRARA, E. ; B. WIDROW.** Fetal Electrocardiogram Enhancement by Time Sequenced Adaptive Filtering. *IEEE Trans. Biomed. Eng.*, June 1982, vol. 29 (6), 458-460 [0009]
- **LONGINI, R. et al.** Near Orthogonal Basis Function: A Real Time Fetal ECG Technique. *IEEE Trans. On Biomedical Eng.*, January 1977, vol. 24 (1), 39-43 [0009]
- **BERGVELD, P. et al.** Real Time Fetal ECG Recording. *IEEE Trans. On Biomedical Eng.*, May 1986, vol. 33 (5), 505-509 [0009]
- **CALLAERTS, D. et al.** Comparison of SVD Methods to Extract the Fetal Electrocardiogram from Cutaneous Electrodes Signals. *Med. & Biol. Eng. & Comput.*, May 1990, vol. 28, 217-224 [0009]
- **ABBOUD, S. et al.** Quantification of the Fetal Electrocardiogram Using Averaging Technique. *Comput. Biol. Med.*, February 1990, vol. 20, 147-155 [0009]
- **CERUTTI, S. et al.** Variability Analysis of Fetal Heart Rate Signals as Obtained from Abdominal Electrocardiographic Recordings. *J. Perinat. Med.*, 1986, vol. 14, 445-452 [0009]
- **J. NAGEL.** Progresses in Fetal Monitoring by Improved Data Acquisition. *IEEE Eng. Med. & Biol. Mag.*, September 1984, vol. 9-13 [0009]
- **OOSTENDORP, T. et al.** The Potential Distribution Generated by Fetal Heart at the Maternal Abdomen. *J. Perinat. Med.*, 1986, vol. 14, 435-444 [0009]
- **MAROSSERO et al.** Independent components analysis for fetal electrocardiogram extraction: a case for the data efficient mermaid algorithm. *NEURAL NETWORKS FOR SIGNAL PROCESSING, NNISP103, IEEE 13TH WORKSHOP ON TOULOUSE*, 17 September 2003, ISBN 0-7803-81 77-7, 399-408 [0010]
- **STURM, R. et al.** Multi-channel magnetocardiography for detecting beat morphology variations in fetal arrhythmias. *Prenat Diagn*, January 2004, vol. 24 (1), 1-9 [0011]
- **STINSTRA, J. et al.** Multicentre study of fetal cardiac time intervals using magnetocardiography. *BJOG*, November 2002, vol. 109 (11), 1235-43 [0011]
- **BELL, A. ; T. SEJNOWSKI.** An Information-Maximization Approach to Blind Separation and Blind Deconvolution. *Neural Computation*, 1995, vol. 7, 1129-1159 [0066]
- **COMON, P.** Independent Component Analysis, A New Concept?. *Signal Processing*, 1994, vol. 36 (3), 287-314 [0066]
- **YANG, H. ; S. AMARI.** Adaptive Online Learning Algorithms for Blind Separation: Maximum Entropy and Minimum Mutual Information. *Neural Computation*, 1997, vol. 9, 1467-1482 [0066]
- **HILD, K. et al.** Blind Source Separation Using Renyi's Mutual Information. *IEEE Signal Processing Letters*, 2001, vol. 8 (6), 174-176 [0066]

专利名称(译)	母胎监测系统		
公开(公告)号	EP1776041B1	公开(公告)日	2019-06-26
申请号	EP2005767705	申请日	2005-05-27
[标]申请(专利权)人(译)	佛罗里达州研究基金会有限公司 收敛ENG		
申请(专利权)人(译)	佛罗里达州研究基金会，Inc.的大学.		
当前申请(专利权)人(译)	佛罗里达州研究基金会，Inc.的大学. 汇聚工程，INC.		
[标]发明人	MAROSSERO DOROTHEE EULIANO TAMMY Y EULIANO NEIL RUSSELL II PRINCIPE JOSE C		
发明人	MAROSSERO, DOROTHEE EULIANO, TAMMY, Y. EULIANO, NEIL, RUSSELL, II PRINCIPE, JOSE, C.		
IPC分类号	A61B5/0444 A61B5/024 A61B5/0488 A61B5/03 A61B5/00 A61B5/0452 A61B5/04 A61B5/103 A61B5/117 A61B10/00 G06F17/00		
CPC分类号	A61B5/0011 A61B5/02411 A61B5/033 A61B5/0444 A61B5/0452 A61B5/04882 A61B5/4362 A61B5/6805 A61B5/6831 A61B5/7264		
代理机构(译)	德哈恩波尔ERIK		
优先权	10/857107 2004-05-28 US		
其他公开文献	EP1776041A2		
外部链接	Espacenet		

摘要(译)

一种母胎监测系统，用于怀孕的所有阶段，包括产前和产时阶段。本发明的母胎监测系统包括（1）一组传感器；（2）放大/滤波装置；（3）计算手段；（4）图形用户界面。使用本发明的系统可以实时提取并提供给用户的准确临床数据包括但不限于母体心电图（ECG）信号，母体子宫活动信号（EHG），母体心率，胎儿ECG信号，和胎心率。在优选实施例中，本发明的母胎监测系统包括智能装置，例如神经网络系统，以分析和解释用于临床诊断产前，产时和产后的临床数据，以及递送策略。

$$FHR_{rev} = \frac{TF}{10} \times FHR + \frac{10 - TF}{10} \times FHR_{rev},$$